UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________
FORM 10-Q
_____________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2017
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission File Number 1-11442
_____________________________________  
CHART INDUSTRIES, INC.
(Exact Name of Registrant as Specified in its Charter)
_____________________________________
Delaware
34-1712937
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
One Infinity Corporate Centre Drive, Suite 300, Garfield Heights, Ohio 44125
(Address of Principal Executive Offices) (ZIP Code)
Registrant’s Telephone Number, Including Area Code: (440) 753-1490
NOT APPLICABLE
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
_____________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
 
Accelerated filer
¨
Non-accelerated filer
¨
(Do not check if a smaller reporting company)
Smaller reporting company
¨
 
 
 
Emerging growth company
¨
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x
At April 24, 2017 , there were 30,716,172 outstanding shares of the Company’s Common Stock, par value $0.01 per share.


CHART INDUSTRIES, INC.
INDEX
 
 
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


2
Table of Contents


PART I. FINANCIAL INFORMATION

Item 1.
Financial Statements
CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share amounts)
 
March 31,
2017
 
December 31,
2016
 
(Unaudited)
 
 
ASSETS
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
$
243,824

 
$
281,959

Accounts receivable, less allowances of $9,868 and $10,217
130,967

 
142,762

Inventories, net
185,275

 
169,683

Unbilled contract revenue
34,288

 
26,736

Prepaid expenses
19,835

 
16,762

Other current assets
18,847

 
15,075

Total Current Assets
633,036

 
652,977

Property, plant, and equipment, net
254,635

 
251,049

Goodwill
228,352

 
217,970

Identifiable intangible assets, net
99,031

 
93,443

Other assets
17,573

 
17,643

TOTAL ASSETS
$
1,232,627

 
$
1,233,082

LIABILITIES AND EQUITY
 
 
 
Current Liabilities
 
 
 
Accounts payable
$
88,872

 
$
79,953

Customer advances and billings in excess of contract revenue
79,399

 
74,702

Accrued salaries, wages, and benefits
27,220

 
41,746

Current portion of warranty reserve
13,197

 
15,293

Short-term debt and current portion of long-term debt
5,073

 
6,487

Other current liabilities
38,366

 
43,353

Total Current Liabilities
252,127

 
261,534

Long-term debt
237,202

 
233,711

Long-term deferred tax liabilities
4,290

 
4,241

Long-term portion of warranty reserve
2,728

 
2,978

Accrued pension liabilities
14,207

 
14,362

Other long-term liabilities
19,150

 
17,579

Total Liabilities
529,704

 
534,405

 
 
 
 
Equity
 
 
 
Common stock, par value $0.01 per share – 150,000,000 shares authorized, 30,713,540 and 30,613,166 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
307

 
306

Additional paid-in capital
400,355

 
395,843

Retained earnings
333,416

 
336,328

Accumulated other comprehensive loss
(32,536
)
 
(35,212
)
Total Chart Industries, Inc. Shareholders’ Equity
701,542

 
697,265

Noncontrolling interests
1,381

 
1,412

Total Equity
702,923

 
698,677

TOTAL LIABILITIES AND EQUITY
$
1,232,627

 
$
1,233,082

The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date, but does not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements.

See accompanying notes to these unaudited condensed consolidated financial statements.

3
Table of Contents


CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(UNAUDITED)
(Dollars and shares in thousands, except per share amounts)
 
Three Months Ended March 31,
 
2017
 
2016
Sales
$
204,095

 
$
193,757

Cost of sales
148,435

 
141,056

Gross profit
55,660

 
52,701

Selling, general, and administrative expenses
52,427

 
49,536

Amortization expense
2,986

 
3,128

Operating expenses
55,413

 
52,664

Operating income
247

 
37

Other expenses:
 
 
 
Interest expense, net
4,378

 
4,094

Financing costs amortization
321

 
321

Foreign currency loss
264

 
206

Other expenses, net
4,963

 
4,621

Loss before income taxes
(4,716
)
 
(4,584
)
Income tax (benefit) expense
(1,764
)
 
88

Net loss
(2,952
)
 
(4,672
)
Noncontrolling interests, net of taxes
(40
)
 
(21
)
Net loss attributable to Chart Industries, Inc.
$
(2,912
)
 
$
(4,651
)
Net loss attributable to Chart Industries, Inc. per common share:
 
 
 
Basic
$
(0.09
)
 
$
(0.15
)
Diluted
$
(0.09
)
 
$
(0.15
)
Weighted-average number of common shares outstanding:
 
 
 
Basic
30,698

 
30,568

Diluted
30,698

 
30,568

 
 
 
 
Comprehensive (loss) income, net of taxes
$
(267
)
 
$
1,844

Less: Comprehensive (loss) income attributable to noncontrolling interests, net of taxes
(31
)
 
3

Comprehensive (loss) income attributable to Chart Industries, Inc., net of taxes
$
(236
)
 
$
1,841


See accompanying notes to these unaudited condensed consolidated financial statements.

4
Table of Contents


CHART INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Dollars in thousands)
 
Three Months Ended March 31,
 
2017
 
2016
OPERATING ACTIVITIES
 
 
 
Net loss
$
(2,952
)
 
$
(4,672
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
Depreciation and amortization
9,161

 
9,479

Interest accretion of convertible notes discount
3,277

 
3,029

Employee share-based compensation expense
6,274

 
5,537

Financing costs amortization
321

 
321

Unrealized foreign currency transaction loss (gain)
193

 
(50
)
Other non-cash operating activities
606

 
506

Changes in assets and liabilities, net of acquisitions:
 
 
 
Accounts receivable
16,178

 
44,126

Inventory
(20,909
)
 
(3,111
)
Unbilled contract revenues and other assets
(4,847
)
 
19,187

Accounts payable and other liabilities
(10,530
)
 
(48,239
)
Customer advances and billings in excess of contract revenue
4,428

 
12,066

Net Cash Provided By Operating Activities
1,200

 
38,179

INVESTING ACTIVITIES
 
 
 
Capital expenditures
(8,386
)
 
(5,232
)
Government grants
145

 
—

Acquisition of businesses, net of cash acquired
(23,162
)
 
—

Net Cash Used In Investing Activities
(31,403
)
 
(5,232
)
FINANCING ACTIVITIES
 
 
 
Borrowings on revolving credit facilities
2,176

 
3,820

Repayments on revolving credit facilities
(3,627
)
 
(3,056
)
Proceeds from exercise of options
32

 
12

Excess tax benefit from share-based compensation
—

 
24

Common stock repurchases
(1,794
)
 
(601
)
Net Cash (Used In) Provided By Financing Activities
(3,213
)
 
199

Effect of exchange rate changes on cash
727

 
2,200

Net (decrease) increase in cash, cash equivalents, restricted cash, and restricted cash equivalents
(32,689
)
 
35,346

Cash, cash equivalents, restricted cash, and restricted cash equivalents
at beginning of period
282,949

 
123,708

CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND RESTRICTED CASH EQUIVALENTS AT END OF PERIOD (1)
$
250,260

 
$
159,054

_______________
(1)  
Includes restricted cash of $6,436 ( $5,446 in other current assets and $990 in other assets) at March 31, 2017 and $990 (in other assets) at March 31, 2016.
See accompanying notes to these unaudited condensed consolidated financial statements.

5
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts)


NOTE 1 — Basis of Preparation
The accompanying unaudited condensed consolidated financial statements of Chart Industries, Inc. and its consolidated subsidiaries (the “Company” or “Chart”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for annual financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 .
Nature of Operations : Chart Industries, Inc. and its consolidated subsidiaries (herein referred to as the “Company,” “Chart,” or “we”), is a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy, and biomedical industries. Chart’s equipment and engineered systems are primarily used for low-temperature and cryogenic applications utilizing our expertise in cryogenic systems and equipment which operate at low temperatures sometimes approaching absolute zero (0 Kelvin; -273° Centigrade; -459° Fahrenheit). The Company has domestic operations located across the United States, including principal executive offices located in Ohio, and an international presence in Asia, Australia, Europe, and South America.
Principles of Consolidation: The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.
Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements. These estimates may also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents: The Company considers all investments with an initial maturity of three months or less when purchased to be cash equivalents. See Debt and Credit Arrangements note for additional information about restricted cash and restricted cash equivalents, which is included in other current assets and other assets in the accompanying condensed consolidated balance sheets.
Recently Issued Accounting Standards: In March 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-07, “Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” The new guidance requires companies with sponsored defined benefit pension and/or other postretirement benefit plans to present the service cost component of net periodic benefit cost in the same income statement line item as other compensation costs. The other components of net periodic benefit cost will be presented separately and not included in operating income. In addition, only service costs are eligible to be capitalized as an asset. The standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those years, and the guidance will generally be applied retroactively, whereas the capitalization of the service cost component will be applied prospectively. Early adoption is permitted with all of the amendments adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the effect that the ASU will have on the Company’s financial position, results of operations, and disclosures.
In January 2017, the FASB issued ASU 2017-04, “Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” The new guidance eliminates the requirement to calculate the implied fair value of goodwill (Step 2 of the current guidance’s goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on current guidance’s Step 1). The guidance will be applied prospectively for annual and interim impairment tests beginning after December 15, 2019. Early adoption is permitted for annual and interim goodwill impairment testing dates after January 1, 2017. The adoption of this ASU would not materially impact the Company’s condensed consolidated financial statements unless Step 1 of the annual goodwill impairment test fails.
In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The FASB issued the update to clarify how entities should classify certain cash receipts and cash payments on the statement of cash flows. The new guidance also clarifies how the predominance principle should be applied when

6
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

cash receipts and cash payments have aspects of more than one class of cash flows. The standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those years, and the guidance will generally be applied retroactively. Early adoption is permitted with all of the amendments adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the effect that the ASU will have on the Company’s condensed consolidated statements of cash flows.
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” The FASB issued the update to require the recognition of lease assets and lease liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on the Company’s financial position, results of operations, cash flows, and disclosures.
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The amendments require entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of the new standard by one year. As a result, the standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within such fiscal years. In March 2016, the FASB issued ASU 2016-08, which amended the principal versus agent guidance in the new revenue standard. This amended guidance is intended to result in a more consistent application and reduce the cost and complexity of applying the new standard. In April 2016, the FASB issued ASU 2016-10, which amended the guidance to clarify accounting for licenses of intellectual property and to clarify the guidance on performance obligations. In May 2016, the FASB issued ASU 2016-12, which provided narrow-scope amendments and practical expedients for the new revenue standard and is intended to reduce the cost and complexity of applying the new standard. In December 2016, the FASB issued ASU 2016-20, which is intended to clarify or correct narrow aspects of the guidance issued in ASU 2014-09. The new revenue recognition ASU allows full retrospective or modified retrospective adoption. Early adoption is permitted as of fiscal years beginning after December 15, 2016. The Company intends to adopt this ASU on January 1, 2018 and has developed an implementation plan to adopt this new guidance. As part of this plan, the Company has identified its revenue streams and is in the process of performing contract reviews to assess the impact of the new guidance on its results of operations. The Company has not yet selected a transition method, but expects to do so in the second quarter of 2017 upon completion of further analysis.
Recently Adopted Accounting Standards: In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.” The FASB issued the update to clarify how restricted cash or restricted cash equivalents should be presented in the statement of cash flows. The standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those years, and the guidance will generally be applied retroactively. Early adoption is permitted with all of the amendments adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period.

The Company is adopting the amendments provided in ASU 2016-18 in these condensed consolidated financial statements to provide financial statement users with more transparent disclosure about restricted cash and restricted cash equivalents. Upon adoption, the amendments provided in this update are applied using a retrospective transition method to each period presented. There was no impact on the condensed consolidated statements of cash flows for the three months ended March 31, 2016, upon adoption of the amendments in this update, because there was no restricted cash or restricted cash equivalents during this period. The cash, cash equivalents, restricted cash, and restricted cash equivalents balance included $6,436 and $990 of restricted cash and restricted cash equivalents at March 31, 2017 and December 31, 2016, respectively. Restricted cash and restricted cash equivalents are included in other current assets and other assets in the accompanying condensed consolidated balance sheets as of March 31, 2017 and December 31, 2016.
In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” The FASB issued the update to change certain aspects of accounting for share-based payments to employees. The update eliminates additional paid-in-capital pools and requires all income tax effects of awards to be recognized in the statements of operations when the awards vest or settle. The ASU allows companies to make an accounting policy election to estimate forfeitures, as required today, or record them when they occur and allows companies to withhold an amount up to the maximum statutory tax rate without causing the award to be classified as a liability. Within the condensed consolidated statements of cash flows, the ASU requires excess tax benefits to be classified as an operating activity and cash payments to tax authorities in connection with shares withheld to be classified as a financing activity. The ASU is effective for

7
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

fiscal years beginning after December 15, 2016, including interim periods within such fiscal years. The Company adopted this guidance effective January 1, 2017.
The Company prospectively recognized the excess income tax effects of awards as income tax expense or benefit in the condensed statements of operations and has elected to continue to estimate the number of share-based awards expected to vest rather than electing to account for forfeitures as they occur. In addition, the Company prospectively recognized the excess tax benefits along with other income tax cash flows as an operating activity in the condensed consolidated statements of cash flows.
In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” The amendments require an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments do not apply to inventory that is measured using the last-in, first-out cost method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. This ASU is effective for fiscal years beginning after December 15, 2016. The Company adopted this guidance prospectively for the fiscal year beginning January 1, 2017. The adoption of the guidance did not have a material impact on the Company’s condensed consolidated financial statements.
NOTE 2 — Inventories
In 2017, the Company prospectively adopted the guidance per ASU 2015-11, “Simplifying the Measurement of Inventory.” The Company previously measured its inventory at the lower of cost or market with cost being determined by the first-in, first-out (“FIFO”) method. Based on the new guidance, the Company measures its inventory at the lower of cost or net realizable value with net realizable value being the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The adoption of the guidance did not have a material impact on the Company’s condensed consolidated financial statements.
The following table summarizes the components of inventory:
 
March 31,
2017
 
December 31,
2016
Raw materials and supplies
$
74,419

 
$
65,719

Work in process
36,698

 
31,576

Finished goods
74,158

 
72,388

Total inventories, net
$
185,275

 
$
169,683

The allowances for excess and obsolete inventory was $9,041 and $10,069 at March 31, 2017 and December 31, 2016 , respectively.
NOTE 3 — Goodwill and Intangible Assets
Goodwill
The following table represents the changes in goodwill by segment:
 
Energy &
Chemicals
 
Distribution & Storage
 
BioMedical
 
Total
Balance at December 31, 2016
$
27,873

 
$
165,520

 
$
24,577

 
$
217,970

Foreign currency translation adjustments and other
—

 
262

 
—

 
262

Goodwill acquired during the year
10,120

 
—

 
—

 
10,120

Balance at March 31, 2017
$
37,993

 
$
165,782

 
$
24,577

 
$
228,352

 
 
 
 
 
 
 
 
Accumulated goodwill impairment loss
$
64,603

 
$
—

 
$
131,243

 
$
195,846


8
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

Intangible Assets
The following table displays the gross carrying amount and accumulated amortization for finite-lived intangible assets and indefinite-lived intangible assets (exclusive of goodwill) (1)(2) :
 
March 31, 2017
 
December 31, 2016
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Finite-lived intangible assets:
 
 
 
 
 
 
 
Unpatented technology
$
8,222

 
$
(3,309
)
 
$
8,186

 
$
(3,132
)
Patents and other
1,882

 
(743
)
 
1,235

 
(695
)
Trademarks and trade names
5,280

 
(2,369
)
 
4,918

 
(2,198
)
Customer relationships
126,845

 
(84,215
)
 
119,320

 
(81,614
)
     Land use rights
12,719

 
(929
)
 
12,650

 
(860
)
Total finite-lived intangible assets
$
154,948

 
$
(91,565
)
 
$
146,309

 
$
(88,499
)
Indefinite-lived intangible assets:
 
 
 
 
 
 
 
Trademarks and trade names
$
35,648

 
—

 
$
35,633

 
—

Total intangible assets
$
190,596

 
$
(91,565
)
 
$
181,942

 
$
(88,499
)
_______________
(1)
Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.
(2)  
The Company amortizes certain identifiable intangible assets primarily on a straight-line basis over their estimated useful lives, which range from one to 50 years.
Expense for intangible assets subject to amortization was $2,986 and $3,128 for the three months ended March 31, 2017 and 2016 , respectively. The Company estimates future amortization expense for its finite-lived intangible assets as follows:
For the Year Ending December 31,
 
2017
$
11,700

2018
10,600

2019
10,600

2020
9,000

2021
2,900

Government Grants
The Company received $145 in government grants during the first three months of 2017 . The government grants are related to property, plant, and equipment and land use rights related to the expansion in China. The grants are recorded in other current liabilities and other long-term liabilities in the condensed consolidated balance sheets and recognized into income over the useful life of the associated assets ( 10 to 50 years).
Government grants at March 31, 2017 and December 31, 2016 are as follows:
 
March 31,
2017
 
December 31,
2016
Current
$
463

 
$
446

Long-term
8,240

 
8,153

Total government grants
$
8,703

 
$
8,599



9
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

NOTE 4 — Debt and Credit Arrangements
Summary of Outstanding Borrowings
The following table represents the components of the Company’s borrowings:
 
March 31,
2017
 
December 31,
2016
Convertible notes, due August 2018, effective interest rate of 7.9%
$
231,392

 
$
228,115

Foreign facilities
11,831

 
13,208

Total debt
243,223

 
241,323

Unamortized debt issuance costs
(948
)
 
(1,125
)
Total debt, net of unamortized debt issuance costs
242,275

 
240,198

Less: current maturities
(5,073
)
 
(6,487
)
Long-term debt
$
237,202

 
$
233,711


Convertible Notes
The outstanding aggregate principal amount of the Company’s 2.0% Convertible Senior Subordinated Notes due 2018 (the “Convertible Notes”) is $250,000 . The Convertible Notes bear interest at a fixed rate of 2.0% per year, payable semiannually in arrears on February 1 and August 1 of each year, and will mature on August 1, 2018. The effective interest rate at issuance was 7.9% .
The Convertible Notes are senior subordinated unsecured obligations of the Company and are not guaranteed by any of the Company’s subsidiaries. The Convertible Notes are senior in right of payment to the Company’s future subordinated debt, equal in right of payment with the Company’s future senior subordinated debt, and are subordinated in right of payment to the Company’s existing and future senior indebtedness, including indebtedness under the Company’s existing credit agreement.
In connection with the issuance of the Convertible Notes, the Company entered into privately-negotiated convertible note hedge and capped call transactions with affiliates of certain of the underwriters (the “Option Counterparties”). The convertible note hedge and capped call transactions relate to, collectively, 3,622 shares, which represents the number of shares of the Company’s common stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes. These convertible note hedge and capped call transactions are expected to reduce the potential dilution with respect to the Company’s common stock upon conversion of the Convertible Notes and/or reduce the Company’s exposure to potential cash or stock payments that may be required upon conversion of the Convertible Notes, except, in the case of the capped call transactions, to the extent that the market price per share of the Company’s common stock exceeds the cap price of the capped call transactions. The Company also entered into separate warrant transactions with the Option Counterparties initially relating to the number of shares of the Company’s common stock underlying the convertible note hedge transactions, subject to customary anti-dilution adjustments. The warrant transactions will have a dilutive effect with respect to the Company’s common stock to the extent that the price per share of the Company’s common stock exceeds the strike price of the warrants unless the Company elects, subject to certain conditions, to settle the warrants in cash. These warrants were exercisable as of the issuance date of the Convertible Notes. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. Proceeds received from the issuance of the warrants totaled approximately $48,848 and were recorded as an addition to additional paid-in-capital. The net cost of the convertible note hedge and capped call transactions, taking into account the proceeds from the issuance of the warrants, was approximately $17,638 .
In accordance with ASC 815, contracts are initially classified as equity if (1) the contract requires physical settlement or net-share settlement, or (2) the contract gives the entity a choice of net-cash settlement in its own shares (physical settlement or net-share settlement). The Company concluded that the settlement terms of the convertible note hedge, capped call, and warrant transactions permit net-share settlement. As such, the convertible note hedge, capped call, and warrant transactions were recorded in equity.
Upon issuance of the Convertible Notes, the Company bifurcated the $250,000 principal balance of the Convertible Notes into a liability component of $170,885 , which was recorded as long-term debt, and an equity component of $79,115 , which was initially recorded as additional paid-in-capital. The liability component was recognized at the present value of its associated cash flows using a 7.9% straight-debt rate which represented the Company’s interest rate for similar debt instruments at that time without

10
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

a conversion feature and is being accreted to interest expense over the term of the Convertible Notes. At March 31, 2017 and December 31, 2016 , the carrying amount of the liability component was $231,392 (less debt issuance costs of $948 ) and $228,115 (less debt issuance costs of $1,125 ), respectively, and the unamortized debt discount of the Convertible Notes was $18,608 and $21,885 , respectively.
For the three months ended March 31, 2017 and 2016 , interest expense for the Convertible Notes was $4,527 and $4,279 , respectively, which included $3,277 and $3,029 of non-cash interest accretion expense related to the carrying amount of the Convertible Notes, respectively, and $1,250 of 2.0% cash interest for both periods. In accordance with ASC 470-20, which requires issuers to separately account for the liability and equity components of convertible debt instruments that may be settled in cash upon conversion, the Company allocated debt issuance costs to the liability and equity components in proportion to their allocated value. Debt issuance costs were $7,277 , with $2,303 recorded as a reduction in additional paid-in-capital. The remaining balance of $4,974 is being amortized over the term of the Convertible Notes. For the three months ended March 31, 2017 and 2016 , total expense associated with the amortization of these debt issuance costs was $178 for both periods.
Prior to May 1, 2018, the Convertible Notes will be convertible at the option of the holders thereof only under the following circumstances: (1) during any fiscal quarter commencing after September 30, 2011 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price (currently $69.03 ) for the Convertible Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “Measurement Period”) in which, as determined following a request by a holder of Convertible Notes as provided in the bond indenture (the “Indenture”), the trading price per $1,000 principal amount of Convertible Notes for each trading day of such Measurement Period was less than 97% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate for the Convertible Notes on each such trading day; or (3) upon the occurrence of specified corporate events pursuant to the terms of the Indenture. On or after May 1, 2018, until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders of the Convertible Notes may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted. It is the Company’s intention to settle any excess conversion value in shares of the Company’s common stock.
The conversion rate on the Convertible Notes will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of a make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate for a holder that converts its Convertible Notes in connection with such make-whole fundamental change. The Company may not redeem the Convertible Notes prior to maturity. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to purchase the Convertible Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the Convertible Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. For purposes of calculating earnings per share, if the average market price of the Company’s common stock exceeds the applicable conversion price during the periods reported, shares contingently issuable under the Convertible Notes will have a dilutive effect with respect to the Company’s common stock.
The Company reassesses the convertibility of the Convertible Notes and the related balance sheet classification on a quarterly basis. At the end of the first quarter of 2017, events for early conversion were not met, and thus the Convertible Notes were not convertible as of and for the fiscal quarter beginning April 1, 2017 . There have been no conversions as of the date of this filing.
Senior Secured Revolving Credit Facility
The Company has a five -year $450,000 senior secured revolving credit facility (the “SSRCF”) which matures on October 29, 2019. The SSRCF includes a $25,000 sub-limit for the issuance of swingline loans and a $100,000 sub-limit to be used for letters of credit. There is a foreign currency limit of $100,000 under the SSRCF which can be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permits borrowings up to $100,000 made by the Company’s wholly-owned subsidiaries, Chart Industries Luxembourg S.à. r.l. (“Chart Luxembourg”) and Chart Asia Investment Company Limited (“Chart Asia”). The SSRCF also includes an expansion option permitting the Company to add up to an aggregate $200,000 in term loans or revolving credit commitments from its lenders.

11
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

The Company recorded $2,869 in deferred debt issuance costs associated with the SSRCF which are being amortized over the five -year term of the SSRCF. For the three months ended March 31, 2017 and 2016 , total expense associated with the amortization of these debt issuance costs was $143 for both periods.
Revolving loans under the SSRCF bear interest, at the applicable Borrower’s election, at either LIBOR or the greatest of (a) the JPMorgan prime rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1%, or (c) the Adjusted LIBOR Rate (as defined in the SSRCF) for the relative interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1% (the “Adjusted Base Rate”), plus a margin that varies with the Company’s leverage ratio. In addition, the Company is required to pay a commitment fee of between 0.25% and 0.40% of the unused revolver balance and a letter of credit participation fee equal to the daily aggregate letter of credit exposure at the rate per annum equal to the Applicable Margin for Eurocurrency Revolving Facility Borrowings (ranging from 1.5% to 2.75% , depending on the leverage ratio calculated at each fiscal quarter end). A fronting fee must be paid on each letter of credit that is issued equal to 0.125% per annum of the stated dollar amount of the letter of credit.
Significant financial covenants for the SSRCF include a minimum liquidity requirement equal to the principal amount of the Convertible Notes outstanding six months prior to the maturity date of the Convertible Notes and when holders of the Convertible Notes have the option to require the Company to repurchase the Convertible Notes, a maximum leverage ratio of 3.25 and a minimum interest coverage to EBITDA ratio of 3.0. The required leverage ratio can be relaxed on up to two occasions, upon notification to the lenders, to 3.75 for up to four consecutive fiscal quarters, for acquisitions and plant expansions of $100,000 or greater. The SSRCF contains a number of other customary covenants including, but not limited to, restrictions on the Company’s ability to incur additional indebtedness, create liens or other encumbrances, sell assets, enter into sale and lease-back transactions, make certain payments, investments, loans, advances or guarantees, make acquisitions and engage in mergers or consolidations, and pay dividends or distributions. At March 31, 2017 , the Company was in compliance with all covenants.
As of March 31, 2017 , there were no borrowings outstanding under the SSRCF. The Company had $35,478 in letters of credit and bank guarantees supported by the SSRCF, which had availability of $414,522 at March 31, 2017 . The obligations under the SSRCF are guaranteed by the Company and substantially all of its U.S. subsidiaries and secured by substantially all of the assets of the Company and its U.S. subsidiaries and 65% of the capital stock of the Company’s material non-U.S. subsidiaries (as defined by the SSRCF) that are owned by U.S. subsidiaries.
Foreign Facilities – China
Chart Cryogenic Engineering Systems (Changzhou) Company Limited (“CCESC”), Chart Energy & Chemicals Wuxi Co., Ltd. (“Wuxi”), and Chart Biomedical (Chengdu) Co. Ltd. (“Chengdu”), wholly-owned subsidiaries of the Company, and Chart Cryogenic Distribution Equipment (Changzhou) Company Limited (“CCDEC”), a joint venture of the Company, maintain joint banking facilities (the “China Facilities”) which include a revolving facility with 50.0 million Chinese yuan (equivalent to $7,247 ) in borrowing capacity which can be utilized for either revolving loans, bonds/guarantees, or bank draft acceptances. Any borrowings made by CCESC, CCDEC, Chengdu, or Wuxi under the China Facilities are guaranteed by the Company. At March 31, 2017 , there were no borrowings outstanding under the revolving facility, but CCESC and CCDEC had 6.1 million Chinese yuan (equivalent to $883 ), and 0.8 million Chinese yuan (equivalent to $122 ) in bank guarantees, respectively.
CCDEC maintains an unsecured credit facility whereby CCDEC may borrow up to 30.0 million Chinese yuan (equivalent to $4,348 ) for working capital purposes. This credit facility is effective until May 25, 2017. At March 31, 2017 , there was 15.0 million Chinese yuan (equivalent to $2,174 ) outstanding under this facility, bearing interest at 4.35% .
CCESC entered into a term loan during the second quarter of 2016. The term loan is secured by certain CCESC land use rights and allows for up to 86.6 million Chinese yuan (equivalent to $12,555 ) in borrowings. The loan has a term of eight years with semi-annual installment payments of at least 10.0 million Chinese yuan and a final maturity date of May 26, 2024. At March 31, 2017 , there was 66.6 million Chinese yuan (equivalent to $9,657 ) outstanding on this loan, bearing interest at 5.39% .
Foreign Facilities – Europe
Chart Ferox, a.s. (“Ferox”), a wholly-owned subsidiary of the Company, maintains a secured credit facility with capacity of up to 125.0 million Czech koruna (equivalent to $4,944 ) and two secured credit facilities with capacity of up to 6.5 million euros (equivalent to $6,949 ). All three facilities allow Ferox to request bank guarantees and letters of credit. None of these facilities allow revolving credit borrowings. Under two of the facilities, Ferox must pay letter of credit and guarantee fees equal to 0.70% per annum on the face amount of each guarantee or letter of credit, and under one facility, Ferox must pay the letter of credit and guarantee fees equal to 0.50% . Ferox’s land, buildings, and cash collateral secure the credit facilities. As of March 31, 2017 , there were bank guarantees of 141.3 million Czech koruna (equivalent to $5,589 ) supported by the Ferox credit facilities.

12
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

Chart Luxembourg maintains an overdraft facility with $5,000 in borrowing capacity. There were no borrowings under the Chart Luxembourg facility as of March 31, 2017 .
Letters of Credit
In August 2016, Chart Energy & Chemicals, Inc. (“Chart E&C”), a wholly-owned subsidiary of the Company, deposited $990 in a bank outside of our credit facility to secure a letter of credit which expires in August 2021. The deposit is treated as restricted cash and restricted cash equivalents and is included in other assets in the condensed consolidated balance sheets as of March 31, 2017 and December 31, 2016.  In February 2017, an additional amount of $5,446 was deposited into the same bank to secure an additional letter of credit which expires in October 2017. The deposit is treated as restricted cash and restricted cash equivalents and is included in other current assets in the condensed consolidated balance sheet as of March 31, 2017. 
Fair Value Disclosures
The fair value of the Convertible Notes was approximately 99% of their par value and approximately 96% of their par value as of March 31, 2017 and December 31, 2016 , respectively. The Convertible Notes are actively quoted instruments and, accordingly, the fair value of the Convertible Notes was determined using Level 1 inputs as defined in Fair Value Measurements note.
NOTE 5 — Derivative Financial Instruments
The Company utilizes certain derivative financial instruments to enhance its ability to manage foreign currency risk that exists as part of ongoing business operations. Derivative instruments are entered into for periods consistent with related underlying exposures and do not constitute positions independent of those exposures. The Company does not enter into contracts for speculative purposes, nor is it a party to any leveraged derivative instrument. The Company is exposed to foreign currency exchange risk as a result of transactions in currencies other than the functional currency of certain subsidiaries. The Company utilizes foreign currency forward purchase and sale contracts to manage the volatility associated with foreign currency purchases and certain intercompany transactions in the normal course of business. Contracts typically have maturities of less than one year. Principal currencies include the U.S. dollar, the euro, the Japanese yen, the Czech koruna, the Australian dollar, the British pound, the Canadian dollar, and the Chinese yuan. The Company’s foreign currency forward contracts do not qualify as hedges as defined by accounting guidance. Foreign currency forward contracts are measured at fair value and recorded on the condensed consolidated balance sheets as other current assets or liabilities and reported as financial assets and liabilities in the Fair Value Measurements note. Changes in their fair value are recorded in the condensed consolidated statements of operations and comprehensive (loss) income as foreign currency gains or losses. The Company’s foreign currency forward contracts are not exchange traded instruments and, accordingly, the valuation is performed using Level 2 inputs as defined in the Fair Value Measurements note. Gains or losses on settled or expired contracts are recorded in the condensed consolidated statements of operations and comprehensive (loss) income as foreign currency gains or losses.
The changes in fair value with respect to the Company’s foreign currency forward contracts generated net losses of $115 and a $148 for the three months ended March 31, 2017 and 2016 , respectively.
NOTE 6 — Product Warranties
The Company provides product warranties with varying terms and durations for the majority of its products. The Company estimates its warranty reserve by considering historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside its typical experience. The Company records warranty expense in cost of sales in the condensed consolidated statements of operations. Product warranty claims not expected to occur within one year are recorded in the long-term portion of the warranty reserve in the condensed consolidated balance sheets.
The following table represents changes in the Company’s consolidated warranty reserve:
Balance at December 31, 2016
$
18,271

Warranty expense
2,047

Warranty usage
(4,393
)
Balance at March 31, 2017
$
15,925


13
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

NOTE 7 — Business Combinations
Hetsco, Inc. Acquisition
On January 13, 2017, the Company acquired 100% of the equity interests in Hetsco, Inc. from Global Power Equipment Group, Inc. for an estimated purchase price of $23,162 , which was paid upon closing. The cash purchase price is subject to post-closing adjustments. The acquisition was accounted for in accordance with ASC Topic 805, Business Combinations. The assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. The estimated fair value of the net assets acquired and goodwill at the date of acquisition was $13,042 and $10,120 respectively. The net assets include an estimate of $8,400 in intangible assets, which consists of customer relationships, certifications and licenses, trade names, backlog, and a non-compete agreement. The purchase price allocation is preliminary and is based on provisional fair values and subject to revision as the Company finalizes third-party valuations and other analyses. Final determination of the fair values may result in further adjustments to the value of net assets acquired.
Hetsco, Inc. is headquartered in Franklin, Indiana and provides emergency, specialty welding and construction services to natural gas processing, petrochemical, and air gas separation industries. Hetsco’s results are included in the Company’s Energy & Chemicals (“E&C”) business segment from the date of acquisition.
Contingent Consideration
The estimated fair value of contingent consideration relating to the 2015 Distribution & Storage (“D&S”) Thermax acquisition was $1,800 at the date of acquisition and was valued according to a discounted cash flow approach, which includes assumptions regarding the probability of achieving certain earnings targets and a discount rate applied to the potential payments. Potential payments may be paid between July 1, 2017 and July 1, 2019 based on the attainment of certain earnings targets. The potential payments related to Thermax contingent consideration are between $0 and $11,288 .
Valuations are performed using Level 3 inputs as defined in the Fair Value Measurements note and are evaluated on a quarterly basis based on forecasted sales and earnings targets. Contingent consideration liabilities are classified as other current liabilities and other long-term liabilities in the condensed consolidated balance sheets. Changes in fair value of contingent consideration, including accretion, are recorded as selling, general, and administrative expenses in the condensed consolidated statements of operations and comprehensive (loss) income.
The following table represents the changes in contingent consideration liabilities:
Balance at December 31, 2016
$
1,923

Increase in fair value of contingent consideration liabilities
1

Balance at March 31, 2017
$
1,924


NOTE 8 — Fair Value Measurements
The Company measures its financial assets and liabilities at fair value on a recurring basis using a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies. The three levels of inputs used to measure fair value are as follows:
Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.
Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
Level 3 — Valuations based on unobservable inputs reflect the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

14
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

Financial assets and liabilities measured at fair value on a recurring basis and presented in the Company’s condensed consolidated balance sheets are as follows:
 
March 31, 2017
 
Total
 
Level 2
 
Level 3
Foreign currency forward contracts
$
7

 
$
7

 
$
—

Total financial assets
$
7

 
$
7

 
$
—

 
 
 
 
 
 
Foreign currency forward contracts
$
190

 
$
190

 
$
—

Contingent consideration liabilities
1,924

 
—

 
1,924

Total financial liabilities
$
2,114

 
$
190

 
$
1,924

 
December 31, 2016
 
Total
 
Level 2
 
Level 3
Foreign currency forward contracts
$
39

 
$
39

 
$
—

Total financial assets
$
39

 
$
39

 
$
—

 
 
 
 
 
 
Foreign currency forward contracts
$
92

 
$
92

 
$
—

Contingent consideration liabilities
1,923

 
—

 
1,923

Total financial liabilities
$
2,015

 
$
92

 
$
1,923

Refer to the Derivative Financial Instruments note for further information regarding derivative financial instruments and the Business Combinations note for further information regarding contingent consideration liabilities.
NOTE 9 — Accumulated Other Comprehensive Loss
The following tables represent changes in accumulated other comprehensive loss by component:
 
Foreign currency translation adjustments
 
Pension liability adjustments, net of taxes
 
Accumulated other comprehensive loss
Balance at December 31, 2016
$
(24,701
)
 
$
(10,511
)
 
$
(35,212
)
Other comprehensive income
2,474

 
—

 
2,474

Amounts reclassified from accumulated other comprehensive loss, net of income taxes of $108 (1)
—

 
202

 
202

Net current-period other comprehensive income, net of taxes
2,474

 
202

 
2,676

Balance at March 31, 2017
$
(22,227
)
 
$
(10,309
)
 
$
(32,536
)
 
Foreign currency translation adjustments
 
Pension liability adjustments, net of taxes
 
Accumulated other comprehensive loss
Balance at December 31, 2015
$
(12,513
)
 
$
(12,391
)
 
$
(24,904
)
Other comprehensive income
6,230

 
—

 
6,230

Amounts reclassified from accumulated other comprehensive loss, net of income taxes of $134 (1)
—

 
250

 
250

Net current-period other comprehensive income, net of taxes
6,230

 
250

 
6,480

Balance at March 31, 2016
$
(6,283
)
 
$
(12,141
)
 
$
(18,424
)

15
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

_______________
(1)  
Amounts reclassified from accumulated other comprehensive loss were expensed and included in cost of sales ( $122 and $151 ) and selling, general, and administrative expenses ( $188 and $233 ) for the three months ended March 31, 2017 and 2016 , respectively, in the condensed consolidated statements of operations and comprehensive (loss) income. The components in accumulated other comprehensive loss are included in the computation of net periodic pension expense as reported in the Employee Benefit Plans note.

NOTE 10 — Loss Per Share
The following table presents calculations of net loss per share of common stock:
 
Three Months Ended March 31,
 
2017
 
2016
Net loss attributable to Chart Industries, Inc.
$
(2,912
)
 
$
(4,651
)
Net loss attributable to Chart Industries, Inc. per common share:
 
 
 
Basic
$
(0.09
)
 
$
(0.15
)
Diluted (1)
$
(0.09
)
 
$
(0.15
)
 
 
 
 
Weighted average number of common shares outstanding — basic
30,698

 
30,568

Incremental shares issuable upon assumed conversion and exercise of share-based awards (1)
—

 
—

Weighted average number of common shares outstanding — diluted
30,698

 
30,568


(1)  
Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs because to do so would be anti-dilutive.
Diluted earnings per share does not reflect the following potential common shares as the effect would be anti-dilutive:
 
Three Months Ended March 31,
 
2017
 
2016
Share-based awards
1,860

 
1,516

Warrants
3,368

 
3,368

Total anti-dilutive securities
5,228

 
4,884

NOTE 11 — Income Taxes
The Company recorded an income tax benefit of $1,764 and expense of $88 in the first quarter of 2017 and 2016 , respectively. The effective income tax rate of 37.4% for the three months ended March 31, 2017 differed from the U.S. federal statutory rate of 35% primarily due to foreign exchange losses realized upon the receipt of previously taxed income and treated as a discrete item for the quarter offset by losses incurred by certain of the Company’s Chinese operations for which no benefit was recorded and the effect of income earned by certain of the Company’s international entities operating in lower taxed jurisdictions. The effective income tax rate of negative 1.9% for the three months ended March 31, 2016 differed from the U.S. federal statutory rate of 35% primarily due to losses incurred by certain Company’s Chinese operations for which no benefit was recorded and the effect of income earned by certain of the Company’s international entities operating in lower taxed jurisdictions.
As of March 31, 2017 and December 31, 2016 , the Company had a liability for gross unrecognized tax benefits of $788. This amount includes $579 of unrecognized tax benefits which, if ultimately recognized, will reduce the Company’s annual effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company had accrued approximately $92 and $86 for the payment of interest and penalties as of March 31, 2017 and December 31, 2016 , respectively.

16
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

NOTE 12 — Employee Benefit Plans
The Company has a frozen defined benefit pension plan that covers certain U.S. hourly and salaried employees. The defined benefit plan provides benefits based primarily on the participants’ years of service and compensation.
The components of net periodic pension expense are as follows :
 
Three Months Ended March 31,
 
2017
 
2016
Interest cost
$
542

 
$
571

Expected return on plan assets
(698
)
 
(697
)
Amortization of net loss
310

 
384

Total net periodic pension expense
$
154

 
$
258


The Company’s funding policy is to contribute at least the minimum funding amounts required by law. Based upon current actuarial estimates, the Company does not expect to contribute to its defined benefit pension plan until 2018.
NOTE 13 — Share-based Compensation
During the three months ended March 31, 2017 , the Company granted 324 stock options, 137 restricted stock units, 7 restricted stock, and 22 performance units. In addition, non-employee directors received 4 stock awards with a fair value of $146 . During the three months ended March 31, 2017 , participants in the Company’s stock option plans exercised options to purchase 1 shares of the Company’s common stock, while 5 stock options were forfeited and 2 stock options expired.
Stock options generally vest ratably over a four-year vesting period. Restricted stock and restricted stock units generally vest ratably over a three-year period. Performance units generally vest at the end of a three-year performance period based on the achievement of certain performance conditions. During the three months ended March 31, 2017 , 118 restricted stock and restricted stock units vested while 2 restricted stock units were forfeited. Also, during the three months ended March 31, 2017 , 22 performance units vested. Additionally, during the three months ended March 31, 2017 , 6 leveraged restricted share units vested.
Share-based compensation expense was $6,274 and $5,537 for the three months ended March 31, 2017 and 2016 , respectively. Share-based compensation expense is included in selling, general, and administrative expenses in the condensed consolidated statements of operations and comprehensive (loss) income. As of March 31, 2017 , total share-based compensation of $10,736 is expected to be recognized over the weighted-average period of approximately 2.68 years .
NOTE 14 — Restructuring Activities
Due to economic conditions, including low energy prices and global competition, the Company implemented a number of cost reduction or avoidance actions, including headcount reductions and facility closures and relocations relating to the consolidation of certain of our facilities in China, Buffalo BioMedical respiratory consolidation, and relocation of the Corporate headquarters.
The following table is a summary of the severance and other restructuring charges for the first quarter ended March 31, 2017 and March 31, 2016 :
 
March 31,
2017
 
March 31,
2016
Severance:
 
 
 
Cost of sales
$
648

 
$
2,361

Selling, general, and administrative expenses
692

 
1,331

Total severance charges
$
1,340

 
$
3,692

Other restructuring:
 
 
 
Cost of sales
$
1,826

 
$
—

Selling, general, and administrative expenses
1,460

 
281

Total other restructuring charges
$
3,286

 
$
281

 
 
 
 
Total restructuring charges
$
4,626

 
$
3,973


17
Table of Contents
CHART INDUSTRIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements – March 31, 2017
(Dollars and shares in thousands, except per share amounts) – Continued

The Company is closely monitoring its end markets and order rates and will continue to take appropriate and timely actions as necessary. The Company currently expects additional restructuring expenses in the remaining nine months of 2017 to be approximately $8,300 ( $3,000 - E&C, $1,300 - D&S, $1,300 - BioMedical, and $2,700 - Corporate), but further actions may be required based on future business conditions.
The following tables summarize the Company’s restructuring activities for the three months ended March 31, 2017 and 2016 :
 
Three Months Ended March 31, 2017
 
Energy & Chemicals
 
Distribution & Storage
 
BioMedical
 
Corporate
 
Total
Balance as of December 31, 2016
$
127

 
$
2,864

 
$
1,308

 
$
3,025

 
$
7,324

Restructuring charges
426

 
137

 
2,604

 
1,459

 
4,626

Cash payments and other
(553
)
 
(736
)
 
(2,473
)
 
(1,553
)
 
(5,315
)
Balance as of March 31, 2017
$
—

 
$
2,265

 
$
1,439

 
$
2,931

 
$
6,635

 
Three Months Ended March 31, 2016
 
Energy & Chemicals
 
Distribution & Storage
 
BioMedical
 
Corporate
 
Total
Balance as of December 31, 2015
$
1,106

 
$
3,446

 
$
430

 
$
850

 
$
5,832

Restructuring charges
292

 
2,193

 
484

 
1,004

 
3,973

Cash payments and other
(854
)
 
(385
)
 
(440
)
 
(779
)
 
(2,458
)
Balance as of March 31, 2016
$
544

 
$
5,254

 
$
474

 
$
1,075

 
$
7,347


NOTE 15 — Reportable Segments
The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company’s operating segments: E&C, D&S, and BioMedical. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, and risk management.
The following table represents information for the Company’s reportable segments and its corporate function:
 
Three Months Ended March 31,
 
2017
 
2016
Sales
 
 
 
Energy & Chemicals
$
39,867

 
$
37,959

Distribution & Storage
113,258

 
107,497

BioMedical
50,970

 
48,301

Consolidated
$
204,095

 
$
193,757

Operating (Loss) Income
 
 
 
Energy & Chemicals
$
(181
)
 
$
(2,198
)
Distribution & Storage
11,593

 
9,830

BioMedical
5,000

 
6,652

Corporate
(16,165
)
 
(14,247
)
Consolidated
$
247

 
$
37



18
Table of Contents


Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
Chart Industries, Inc. (the “Company,” “Chart,” or “we”) is a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy, and biomedical industries. Our equipment and engineered systems are primarily used for low-temperature and cryogenic applications utilizing our expertise in cryogenic systems and equipment which operate at low temperatures sometimes approaching absolute zero (0 Kelvin; -273° Centigrade; -459° Fahrenheit).
Sales for the three months ended March 31, 2017 were $204.1 million compared to sales of $193.8 million for the three months ended March 31, 2016 , reflecting an increase of $10.3 million , or 5.3% . This increase was attributable to higher sales in all of our segments, primarily in the D&S segment. Sequentially over the fourth quarter of 2016, sales decreased $10.3 million as several European LNG projects in the D&S segment did not recur in the first quarter of 2017. Gross profit for the three months ended March 31, 2017 was $55.7 million , or 27.3% of sales, compared to $52.7 million , or 27.2% of sales, for the three months ended March 31, 2016 . Gross profit increased during the first three months of 2017 mainly due to an increase in sales volume across all the segments. Energy & Chemicals (“E&C”) contributed an additional $3.0 million primarily due to improved project execution, which was partially offset by restructuring costs incurred, largely within the BioMedical segment. Gross profit for the fourth quarter of 2016 was $57.1 million or 26.6% of sales which included $0.9 million of restructuring costs.
Restructuring expenses of $4.6 million for the first three months of 2017 were recorded in cost of goods sold ($2.5 million) and selling, general, and administrative expenses (“SG&A”) ($2.1 million) as a result of our cost reduction and operating efficiency initiatives primarily related to the previously announced corporate office relocation and the Buffalo BioMedical respiratory consolidation to our Canton, Georgia facilities. SG&A was up $2.9 million or 5.8% compared to the first quarter of 2016 largely within Corporate which included restructuring charges and acceleration of share-based compensation expense for retirement eligible participants. SG&A in the fourth quarter of 2016 was $52.0 million, inclusive of $3.8 million of severance and other restructuring costs. Operating income for the three months ended March 31, 2017 was $0.2 million compared to $0.04 million for the three months ended March 31, 2016 , for the reasons discussed above.
Low energy prices and significant new liquefied natural gas (“LNG”) export capacity continue to delay new LNG liquefaction opportunities, which has negatively impacted our sales and order trends over the last few years, particularly in the E&C segment. Current forecasts are for LNG supply/demand balance to be reached in 2020-2022 indicating that new LNG liquefaction projects need to go forward in the 2018 time frame to meet demand growth forecasts. In addition, global competition and customer consolidation continue to put pressure on pricing generally. Sequentially over the fourth quarter of 2016, orders were up in all three business segments. We have begun to see a rebound in order and quotation activity related to equipment for cryogenic gas plant development driven by drilling activity in the Permian and Scoop & Stack basins. In the first quarter of 2017, we received equipment orders for eight natural gas processing plants compared to zero received in the full year 2016. This increased natural gas liquids (“NGL”) production is also creating new potential opportunities for Ethylene and Propylene production plants. Orders and customer discussion for D&S equipment are improving globally but particularly in North America. We currently expect future restructuring expenses in 2017 to total approximately $8.3 million, primarily associated with the corporate office relocation and consolidation of certain facilities in China. We expect our restructuring initiatives will equate to annualized savings of approximately $10 million.


19
Table of Contents


The following table includes key metrics used to evaluate our business and measure our performance and represents selected financial data for our operating segments for the three months ended March 31, 2017 and 2016 and December 31, 2016. Financial data for the three months ended December 31, 2016 has been included to provide additional information regarding our business trends on a sequential quarter basis (dollars in thousands):
 
Three Months Ended
 
March 31, 2017
 
March 31, 2016
 
December 31, 2016
Sales
 
 
 
 
 
Energy & Chemicals
$
39,867

 
$
37,959

 
$
31,384

Distribution & Storage
113,258

 
107,497

 
133,394

BioMedical
50,970

 
48,301

 
49,594

Consolidated
$
204,095

 
$
193,757

 
$
214,372

Gross Profit
 
 
 
 
 
Energy & Chemicals
$
8,425

 
$
5,471

 
$
5,756

Distribution & Storage
30,548

 
29,415

 
34,220

BioMedical
16,687

 
17,815

 
17,122

Consolidated
$
55,660

 
$
52,701

 
$
57,098

Gross Profit Margin
 
 
 
 
 
Energy & Chemicals
21.1
 %
 
14.4
 %
 
18.3
 %
Distribution & Storage
27.0
 %
 
27.4
 %
 
25.7
 %
BioMedical
32.7
 %
 
36.9
 %
 
34.5
 %
Consolidated
27.3
 %
 
27.2
 %
 
26.6
 %
SG&A Expenses
 
 
 
 
 
Energy & Chemicals
$
7,802

 
$
7,065

 
$
6,128

Distribution & Storage
17,758

 
17,943

 
20,229

BioMedical
10,817

 
10,299

 
12,403

Corporate
16,050

 
14,229

 
13,289

Consolidated
$
52,427

 
$
49,536

 
$
52,049

SG&A Expenses (% of Sales)
 
 
 
 
 
Energy & Chemicals
19.6
 %
 
18.6
 %
 
19.5
 %
Distribution & Storage
15.7
 %
 
16.7
 %
 
15.2
 %
BioMedical
21.2
 %
 
21.3
 %
 
25.0
 %
Consolidated
25.7
 %
 
25.6
 %
 
24.3
 %
Operating (Loss) Income (1)
 
 
 
 
 
Energy & Chemicals
$
(181
)
 
$
(2,198
)
 
$
(883
)
Distribution & Storage
11,593

 
9,830

 
12,885

BioMedical
5,000

 
6,652

 
3,847

Corporate
(16,165
)
 
(14,247
)
 
(13,517
)
Consolidated
$
247

 
$
37

 
$
2,332

Operating Margin
 
 
 
 
 
Energy & Chemicals
(0.5
)%
 
(5.8
)%
 
(2.8
)%
Distribution & Storage
10.2
 %
 
9.1
 %
 
9.7
 %
BioMedical
9.8
 %
 
13.8
 %
 
7.8
 %
Consolidated
0.1
 %
 
—
 %
 
1.1
 %
_______________
(1) Includes restructuring costs of $4.6 million , ($0.4 million - E&C, $0.1 million - D&S, $2.6 million BioMedical, and $1.5 million - Corporate) and $4.0 million ($0.3 million - E&C, $2.2 million - D&S, $0.5 million BioMedical, and $1.0 million - Corporate), and $4.7 million ($0.1 million - E&C, $0.1 million - D&S, $1.4 million - BioMedical, and $3.1 million - Corporate) for the three months ended March 31, 2017 and 2016, and December 31, 2016, respectively.

20
Table of Contents


Results of Operations for the Three Months Ended March 31, 2017 Compared to the Three Months Ended March 31, 2016
Sales
Sales for the three months ended March 31, 2017 were $204.1 million compared to $193.8 million for the three months ended March 31, 2016 , reflecting an increase of $10.3 million , or 5.3% with each of the business segments showing an increase of at least 5% compared to the prior year quarter. Sales were down $10.3 million or 4.8%, sequentially, over the fourth quarter of 2016 sales of $214.4 million, for the reasons described above.
E&C segment sales increased by $1.9 million , or 5.0% , compared to the same quarter in the prior year. The increase is primarily due to the addition of our Lifecycle business which includes the results of the Hetsco acquisition in the first three months of 2017. Sequentially to the fourth quarter of 2016, sales were up $8.5 million, with improvement across the product lines.
D&S segment sales increased by $5.8 million, or 5.3% , compared to the same quarter in the prior year, with improved volume in all the regions. Sales increased in the current quarter versus the same quarter in the prior year due to a $9.6 million increase in sales for liquefied natural gas applications and a $1.5 million increase in packaged industrial gas applications, offset by a decrease of $5.4 million in bulk industrial gas applications. Sequentially to the fourth quarter of 2016, sales were down $20.1 million or 15.1%. Fourth quarter 2016 included several LNG projects in Europe, which did not recur in the first quarter of 2017.
BioMedical segment sales increased by $2.7 million , or 5.5% , compared to the same quarter in the prior year, primarily attributed to a $2.8 million increase in sales related to respiratory therapy equipment primarily outside the United States. Sequentially to the fourth quarter of 2016, sales increased $1.4 million, or 2.8%, with increases in respiratory and cryobiological sales primarily outside the United States.
Gross Profit and Margin
Gross profit for the three months ended March 31, 2017 was $55.7 million , or 27.3% of sales, versus $52.7 million , or 27.2% of sales, for the three months ended March 31, 2016 , which reflected an increase of $3.0 million , while the related margin percentage increased by 0.1 percentage points. Gross profit for the fourth quarter of 2016 was $57.1 million or 26.6% of sales which included $0.9 million of restructuring costs.
E&C segment gross profit increased $3.0 million and the related margin increased 6.7 percentage points compared to the same quarter in the prior year, primarily due to our Systems business as project margins were higher due to favorable project execution. E&C segment gross profit increased $2.7 million and the related margin increased 2.8 percentage points compared sequentially to the fourth quarter of 2016; the sequential improvement is attributed to improved cost structure and favorable project mix.
D&S segment gross profit increased by $1.1 million and the related margin decreased by 0.4 percentage points compared to the same quarter in the prior year. The prior year’s first quarter included the favorable impact of an insurance settlement (approximately $1.0 million) and unfavorable restructuring expenses of $1.8 million. D&S segment gross profit decreased $3.7 million and the related margin increased 1.3 percentage points compared sequentially to the fourth quarter of 2016, largely due to improvements in our Asian operations.
BioMedical segment gross profit decreased by $1.1 million and the related margin decreased by 4.2 percentage points compared to the same quarter in the prior year as improved volume was partially offset by the impact of restructuring expenses ($2.1 million). BioMedical segment gross profit decreased $0.4 million and the related margin decreased by 1.8 percentage points, compared sequentially to the fourth quarter of 2016 which included $0.9 million of restructuring expenses.
SG&A
SG&A expenses for the three months ended March 31, 2017 were $52.4 million , or 25.7% of sales, compared to $49.5 million , or 25.6% of sales, for the three months ended March 31, 2016 , representing an increase of $2.9 million . SG&A expenses related to restructuring activities for the three months ended March 31, 2017 included $2.1 million of restructuring costs primarily pertaining to the corporate office relocation and the Buffalo BioMedical respiratory consolidation, compared to $1.6 million in the first three months of 2016, which was primarily related to severance at Corporate, as well as expenses associated with the Owatonna facility closure. Additionally, SG&A expenses were higher compared to the prior year quarter primarily due to higher share-based compensation expense for retirement eligible participants. SG&A in the fourth quarter of 2016 was $52.0 million, inclusive of $3.8 million of severance and other restructuring costs. The sequential increase from the fourth quarter of 2016 to the first quarter of 2017 was $0.4 million.
E&C segment SG&A expenses increased by $0.8 million compared to the prior year period primarily due to the addition of our Lifecycle business which was new in 2016 and includes our acquisition of Hetsco in the first quarter of 2017.
D&S segment SG&A expenses decreased by $0.2 million compared to the same quarter in the prior year. D&S SG&A decreased $2.5 million compared to fourth quarter of 2016 which included higher bad debt expenses.

21
Table of Contents


BioMedical segment SG&A expenses increased by $0.5 million compared to the same quarter in the prior year and included $0.5 million of restructuring expenses. BioMedical segment SG&A expenses decreased by $1.6 million compared sequentially to the fourth quarter of 2016, primarily due to higher incentives, commission expenses, and bad debt expenses in the fourth quarter of 2016.
Corporate SG&A expenses increased by $1.8 million compared to the prior year period primarily due to acceleration of retirement eligible stock compensation expense, which is higher than the comparable amounts in the prior year, and higher restructuring costs. Sequentially, expenses are up $2.7 million which includes the acceleration of retirement eligible share-based compensation expense, partially offset by lower restructuring costs compared to the fourth quarter of 2016.
Operating Income
As a result of the foregoing, operating income for the three months ended March 31, 2017 was $0.2 million , an increase of $0.2 million , or 0.1% of sales, compared to operating income of $0.04 million , or less than 0.1% of sales, for the same quarter in 2016 .
Interest Expense, Net and Financing Costs Amortization
Net interest expense for the three months ended March 31, 2017 and 2016 was $4.4 million and $4.1 million , respectively. Interest expense for the three months ended March 31, 2017 included $1.3 million of 2.0% cash interest and $3.3 million of non-cash interest accretion expense related to the carrying value of the Convertible Notes. For each of the three months ended March 31, 2017 and 2016, financing costs amortization was $0.3 million .
Income Tax (Benefit) Expense
Income tax benefit of $1.8 million and expense of $0.1 million for the three months ended March 31, 2017 and 2016 , respectively, represents taxes on both U.S. and foreign earnings at a combined effective income tax rate of 37.4% and negative 1.9% , respectively. The effective income tax rate of 37.4% for the first quarter of 2017 was higher than the U.S. federal statutory rate of 35% primarily due to foreign exchange losses realized upon the receipt of previously taxed income and treated as a discrete item for the quarter and losses incurred by certain of our Chinese operations for which no tax benefit was recorded, partially offset by the effect of income earned by certain of our international entities operating in lower taxed jurisdictions. The effective income tax rate of negative 1.9% for the three months ended March 31, 2016 differed from the U.S. federal statutory rate of 35% primarily due to losses incurred by certain of our Chinese operations for which no benefit was recorded and the effect of income earned by certain of our international entities operating in lower taxed jurisdictions.
Net Loss
As a result of the foregoing, net loss attributable to the Company for the three months ended March 31, 2017 and 2016 was $2.9 million and $4.7 million , respectively.
Liquidity and Capital Resources
Debt Instruments and Related Covenants
Convertible Notes: The outstanding aggregate principal amount of the Company’s Convertible Notes is $250.0 million. The Convertible Notes bear interest at a fixed rate of 2.0% per year, payable semiannually in arrears on February 1 and August 1 of each year, and will mature on August 1, 2018. The effective interest rate at issuance, under generally accepted accounting principles, was 7.9%. Upon conversion, holders of the Convertible Notes will receive cash up to the principal amount of the Convertible Notes. It is the Company’s intention to settle any excess conversion value in shares of the Company’s common stock. However, the Company may elect to settle, at its discretion, any such excess value in cash, shares of the Company’s common stock, or a combination of cash and shares. The initial conversion price of $69.03 per share represents a conversion premium of 30% over the last reported sale price of the Company’s common stock on July 28, 2011, the date of the Convertible Notes offering, which was $53.10 per share. At the end of the first quarter of 2017 , events for early conversion were not met; and thus, the Convertible Notes were not convertible as of, and for the fiscal quarter beginning April 1, 2017 . There have been no conversions as of the date of this filing. In the event that holders of Convertible Notes elect to convert, the Company expects to fund any cash settlement of any such conversion from cash balances or borrowings under its senior secured revolving credit facility.
Senior Secured Revolving Credit Facility: The Company has a five-year $450.0 million senior secured revolving credit facility (the “SSRCF”) which matures on October 29, 2019. The SSRCF includes a $25.0 million sub-limit for the issuance of

22
Table of Contents


swingline loans and a $100.0 million sub-limit to be used for letters of credit. There is a foreign currency limit of $100.0 million under the SSRCF which can be used for foreign currency denominated letters of credit and borrowings in a foreign currency, in each case in currencies agreed upon with the lenders. In addition, the facility permits borrowings up to $100.0 million made by the Company’s wholly-owned subsidiaries, Chart Industries Luxembourg S.à r.l. (“Chart Luxembourg”), and Chart Asia Investment Company Limited. The SSRCF also includes an expansion option permitting the Company to add up to an aggregate $200.0 million in term loans or revolving credit commitments from its lenders. Loans under the SSRCF bear interest at LIBOR or the Adjusted Base Rate as defined in the Debt and Credit Arrangements note to our condensed consolidated financial statements included elsewhere in this report, plus a margin that varies with the Company’s leverage ratio. Significant financial covenants for the SSRCF include a leverage ratio and an interest ratio. As of March 31, 2017 , there were no borrowings outstanding under the SSRCF. The Company had $35.5 million in letters of credit and bank guarantees supported by the SSRCF, which had availability of $414.5 million , at March 31, 2017 . The Company was in compliance with all covenants, including its financial covenants at March 31, 2017 .
Foreign Facilities – China: Chart Cryogenic Engineering Systems (Changzhou) Company Limited (“CCESC”), Chart Energy & Chemicals Wuxi Co., Ltd. (“Wuxi”), and Chart Biomedical (Chengdu) Co. Ltd. (“Chengdu”), wholly-owned subsidiaries of the Company, and Chart Cryogenic Distribution Equipment (Changzhou) Company Limited (“CCDEC”), a joint venture of the Company, maintain joint banking facilities (the “China Facilities”) which include a revolving facility with 50.0 million Chinese yuan (equivalent to $7.2 million ) in borrowing capacity which can be utilized for either revolving loans, bonds/guarantees, or bank draft acceptances. Any borrowings made by CCESC, CCDEC, Chengdu, or Wuxi under the China Facilities are guaranteed by the Company. At March 31, 2017 , there were no borrowings under the revolving facility, but CCESC and CCDEC had 6.1 million Chinese yuan (equivalent to $0.9 million ) and 0.8 million Chinese yuan (equivalent to $0.1 million ) in bank guarantees, respectively.
CCDEC maintains an unsecured credit facility whereby CCDEC may borrow up to 30.0 million Chinese yuan (equivalent to $4.3 million ) for working capital purposes. This credit facility is effective until May 25, 2017. At March 31, 2017 there was 15.0 million Chinese yuan (equivalent to $2.2 million ) outstanding under this facility, bearing interest at 4.35% .
CCESC entered into a term loan during the second quarter of 2016. The term loan is secured by certain CCESC land use rights and allows for up to 86.6 million Chinese yuan (equivalent to $12.6 million ) in borrowings. The loan has a term of eight years with semi-annual installment payments of at least 10.0 million Chinese yuan and a final maturity date of May 26, 2024. At March 31, 2017 , there was 66.6 million Chinese yuan (equivalent to $9.7 million ) outstanding on this loan, bearing interest at 5.39% .
Foreign Facilities – Europe: Chart Ferox, a.s. (“Ferox”), a wholly-owned subsidiary of the Company, maintains a secured credit facility with capacity of up to 125.0 million Czech koruna (equivalent to $4.9 million ) and two secured credit facilities with capacity of up to 6.5 million euros (equivalent to $6.9 million ). All three facilities allow Ferox to request bank guarantees and letters of credit. None of these facilities allow revolving credit borrowings. Under two of the facilities, Ferox must pay letter of credit and guarantee fees equal to 0.70% per annum on the face amount of each guarantee or letter of credit, and under one facility, Ferox must pay the letter of credit and guarantee fees equal to 0.50% . Ferox’s land, buildings and cash collateral secure the credit facilities. As of March 31, 2017 , there were bank guarantees of 141.3 million Czech koruna (equivalent to $5.6 million ) supported by the Ferox credit facilities.
Chart Luxembourg maintains an overdraft facility with $5.0 million in borrowing capacity. There were no borrowings under the Chart Luxembourg facility as of March 31, 2017 .
Our debt and related covenants are further described in the Debt and Credit Arrangements note to our condensed consolidated financial statements included elsewhere in this report.
Sources and Use of Cash
Our cash and cash equivalents totaled $243.8 million at March 31, 2017 , a decrease of $38.1 million from the balance at December 31, 2016 . Our foreign subsidiaries held cash of approximately $70.1 million and $72.9 million , at March 31, 2017 , and December 31, 2016 , respectively, to meet their liquidity needs. No material restrictions exist to accessing cash held by our foreign subsidiaries. We expect to meet our U.S. funding needs without repatriating non-U.S. cash and incurring incremental U.S. taxes. Cash equivalents are invested in money market funds that invest in high quality, short-term instruments, such as U.S. government obligations, certificates of deposit, repurchase obligations, and commercial paper issued by corporations that have been highly rated by at least one nationally recognized rating organization, and in the case of cash equivalents in China, obligations of local banks. We believe that our existing cash and cash equivalents, funds available under our SSRCF, and cash provided by operations will be sufficient to finance our normal working capital needs, acquisitions, and investments in properties, facilities, and equipment for the foreseeable future.

23
Table of Contents


Cash provided by operating activities was $1.2 million for the three months ended March 31, 2017 compared to $38.2 million of cash provided by operating activities for the three months ended March 31, 2016. The decrease in cash provided by operations is primarily due to timing of receipts and payments for inventory, offset by the timing of cash payments from customers.
Cash used in investing activities was $31.4 million , and $5.2 million for the three months ended March 31, 2017 and 2016, respectively. During the three months ended March 31, 2017, we used $23.2 million of cash related to the Hetsco acquisition and $8.4 million for capital expenditures.
Cash used in financing activities was $3.2 million for the three months ended March 31, 2017 whereas cash provided by financing activities was $0.2 million for the three months ended March 31, 2016 . During the three months ended March 31, 2017 , we borrowed 15.0 million Chinese yuan (equivalent to $2.2 million) and repaid 25.0 million Chinese yuan (equivalent to $3.6 million) on our China Facilities. We used $1.8 million for the purchase of common stock which was surrendered to cover tax withholding elections during the three months ended March 31, 2017 .
Accounts Receivable and Allowance for Doubtful Accounts
Our accounts receivable, net, balance was $131.0 million at March 31, 2017 compared to $142.8 million at December 31, 2016 , representing a decrease of $11.8 million . Our accounts receivable allowance was $9.9 million at March 31, 2017 and $10.2 million at December 31, 2016 . The reserve includes approximately $6.5 million attributed to receivables in China in light of the economic environment and collection challenges in China.
Cash Requirements
We do not currently anticipate any unusual cash requirements for working capital needs for the year ending December 31, 2017 . Management anticipates we will be able to satisfy cash requirements for our ongoing business for the foreseeable future with cash generated by operations, existing cash balances, and available borrowings under our credit facilities. We may repurchase a portion of our Convertible Notes on the open market from time to time to the extent permitted by our debt covenants with available cash. To the extent that we repurchase Convertible Notes, we would expect to enter into an agreement with each of the Option Counterparties to our convertible note hedge, warrant, and capped call agreements providing for the partial unwind of such agreements in a notional amount corresponding to the aggregate principal amount of Convertible Notes that we repurchase. We expect capital expenditures for the remaining nine months of 2017 to be $35.0 million to $45.0 million , which will be deployed primarily for an expansion of the brazed aluminum heat exchanger facility in La Crosse, Wisconsin, as well as cost saving improvement projects and routine maintenance across all businesses. For the remaining nine months of 2017, we contemplate the use of approximately $16.0 million to $18.0 million of cash to pay U.S. and foreign income taxes.

24
Table of Contents


Orders and Backlog
We consider orders to be those for which we have received a firm signed purchase order or other written contractual commitment from the customer. Backlog is comprised of the portion of firm signed purchase orders or other written contractual commitments received from customers that we have not recognized as revenue upon shipment or under the percentage of completion method. Backlog can be significantly affected by the timing of orders for large projects, particularly in the E&C segment, and is not necessarily indicative of future backlog levels or the rate at which backlog will be recognized as sales. Orders included in our backlog may include customary cancellation provisions under which the customer could cancel part or all of the order, potentially subject to the payment of certain costs and/or fees. Backlog may be negatively impacted by ability or likelihood of customers to fulfill their obligations. Our backlog as of March 31, 2017 was $348.6 million compared to $342.6 million as of December 31, 2016 and $382.4 million as of March 31, 2016.
The table below represents orders received and backlog by segment for the periods indicated (dollar amounts in thousands):
 
Three Months Ended
 
March 31,
2017
 
March 31,
2016
 
December 31,
2016
Orders
 
 
 
 
 
Energy & Chemicals
$
37,981

 
$
8,774

 
$
20,495

Distribution & Storage
119,968

 
139,376

 
114,616

BioMedical
51,744

 
51,109

 
48,891

Total
$
209,693

 
$
199,259

 
$
184,002

 
As of
 
March 31,
2017
 
March 31,
2016
 
December 31,
2016
Backlog
 
 
 
 
 
Energy & Chemicals
$
98,028

 
$
122,648

 
$
99,842

Distribution & Storage
224,978

 
239,978

 
218,210

BioMedical
25,550

 
19,819

 
24,571

Total
$
348,556

 
$
382,445

 
$
342,623

E&C orders for the three months ended March 31, 2017 were $38.0 million compared to $20.5 million for the three months ended December 31, 2016 and $8.8 million for the three months ended March 31, 2016. Orders increased across product lines in E&C as we have begun to see signs of recovery in the energy related markets; orders in the first quarter of 2017 include the Bechtel FEED study for Tellurian LNG as well as equipment orders for eight natural gas processing plants. E&C backlog totaled $98.0 million at March 31, 2017 , compared to $99.8 million as of December 31, 2016 . Included in the E&C backlog is approximately $40 million related to the previously announced Magnolia LNG order where production release is delayed into 2018. Order flow in the E&C segment is historically volatile due to project size and it is not unusual to see order intake change significantly year over year.
D&S orders for the three months ended March 31, 2017 were $120.0 million compared to $114.6 million for the three months ended December 31, 2016 and $139.4 million for the three months ended March 31, 2016. The increase in D&S orders from the fourth quarter of 2016 was primarily attributable to a $14.7 million increase in bulk industrial gas applications, offset by an $9.3 million decrease in orders for packaged LNG. The decrease in D&S orders when compared to the same quarter last year was primarily due to the inclusion of the AB Klaipedos nafta LNG order in the first quarter of the prior year. D&S backlog totaled $225.0 million at March 31, 2017 compared to $218.2 million as of December 31, 2016 and $240.0 million as of March 31, 2016.
BioMedical orders for the three months ended March 31, 2017 were $51.7 million compared to $48.9 million for the three months ended December 31, 2016 and $51.1 million for the three months ended March 31, 2016. The increase from the fourth quarter of 2016 in BioMedical orders was attributable increases of $1.5 million and $1.8 million in respiratory therapy applications and life sciences, respectively. BioMedical backlog at March 31, 2017 totaled $25.6 million compared to $24.6 million as of December 31, 2016 and $19.8 million as of March 31, 2016.
Off-Balance Sheet Arrangements
We do not have any material off-balance sheet arrangements.

25
Table of Contents


Application of Critical Accounting Policies
The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. As such, some accounting policies have a significant impact on amounts reported in these condensed consolidated financial statements. A summary of those significant accounting policies can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . In particular, judgment is used in areas such as revenue recognition for long-term contracts, goodwill, indefinite-lived intangibles, long-lived assets, product warranty costs, and pensions. There have been no significant changes to our critical accounting policies since December 31, 2016 .
Forward-Looking Statements
The Company is making this statement in order to satisfy the “safe harbor” provisions contained in the Private Securities Litigation Reform Act of 1995. This Quarterly Report on Form 10-Q includes “forward-looking statements.” These forward-looking statements include statements relating to our business. In some cases, forward-looking statements may be identified by terminology such as “may,” “should,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “continue,” or the negative of such terms or comparable terminology. Forward-looking statements contained herein (including future cash contractual obligations, liquidity, cash flow, orders, results of operations, projected revenues, and trends, among other matters) or in other statements made by us are made based on management’s expectations and beliefs concerning future events impacting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by forward-looking statements. We believe that the following factors, among others (including those described under Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016 ), could affect our future performance and the liquidity and value of our securities and cause our actual results to differ materially from those expressed or implied by forward-looking statements made by us or on our behalf:
• the cyclicality of the markets which we serve and the vulnerability of those markets to economic downturns;
•
the loss of, or a significant reduction or delay in purchases by, our largest customers;
•
our ability to control our costs and successfully manage our operations;
•
fluctuations in energy prices;
•
competition in our markets;
•
the potential for negative developments in the natural gas industry related to hydraulic fracturing;
•
the impairment of our goodwill or other intangible assets;
•
degradation of our backlog as a result of modification or termination of orders;
•
our ability to successfully acquire or integrate companies that provide complementary products or technologies;
•
governmental energy policies could change, or expected changes could fail to materialize;
•
our ability to manage our fixed-price contract exposure;
•
economic downturns and deteriorating financial conditions;
•
our reliance on the availability of key supplies and services;
•
changes in government health care regulations and reimbursement policies;
•
litigation and disputes involving us, including the extent of product liability, warranty, contract, employment, intellectual property and environmental claims asserted against us;
•
fluctuations in foreign currency exchange rates and interest rates;
•
the loss of key employees;
•
general economic, political, business and market risks associated with our global operations, including collection issues related to receivables in China;
•
our warranty reserves may not adequately cover our warranty obligations;
•
technological security threats and our reliance on information systems;
•
financial distress of third parties;
•
our ability to protect our intellectual property and know-how;
•
United States Food and Drug Administration and comparable foreign regulation of our products;
•
the pricing and availability of raw materials;
•
claims that our products or processes infringe intellectual property rights of others;
•
the cost of compliance with environmental, health, and safety laws and responding to potential liabilities under these laws;

26
Table of Contents


•
additional liabilities related to taxes;
•
our ability to continue our technical innovation in our product lines;
•
the underfunded status of our pension plan;
•
the risk of potential violations of the Foreign Corrupt Practices Act;
•
increased government regulation;
•
labor costs and disputes and the deterioration of our relations with our employees;
•
disruptions in our operations due to severe weather;
•
regulations governing the export of our products and other regulations applicable to us as a supplier of products to the U.S. government;
•
fluctuations or adjustments in the Company’s effective tax rate;
•
risks associated with our indebtedness, leverage and liquidity;
•
fluctuations in the price of our stock;
•
potential dilution to existing holders of our common stock as a result of the conversion of our Convertible Notes, and the need to utilize our cash balances and/or credit facility to fund any cash settlement related to such conversions; and
•
other factors described herein.
There may be other factors that may cause our actual results to differ materially from the forward-looking statements.
All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date of this Quarterly Report and are expressly qualified in their entirety by the cautionary statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 , as the same may be updated from time to time. We undertake no obligation to update or revise forward-looking statements which may be made to reflect events or circumstances that arise after the filing date of this document or to reflect the occurrence of unanticipated events.
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
In the normal course of business, the Company’s operations are exposed to fluctuations in interest rates and foreign currency values that can affect the cost of operating and financing. Accordingly, the Company addresses a portion of these risks through a program of risk management.
Interest Rate Risk: The Company’s primary interest rate risk exposure results from the SSRCF’s various floating rate pricing mechanisms. Based on zero borrowings outstanding under the SSRCF as of March 31, 2017 , the Company believes that interest rate exposure is not a material risk to the Company at this time.
Foreign Currency Exchange Rate Risk: The Company operates in the United States, Asia, Australia, Europe, and South America, creating exposure to foreign currency exchange fluctuations in the normal course of business, which can impact our financial position, results of operations, cash flow, and competitive position. The financial statements of foreign subsidiaries are translated into their U.S. dollar equivalents at end-of-period exchange rates for assets and liabilities, while income and expenses are translated at average monthly exchange rates. Translation gains and losses are components of other comprehensive (loss) income as reported in the condensed consolidated statements of operations and comprehensive (loss) income. Translation exposure is primarily with the euro, the Chinese yuan, and the J apanese yen. During the first quarter of 2017 , the euro, Chinese yuan, and Japanese yen decreased in relation to the U.S. dollar by 1% , 1%, and 4%, r espectively. At March 31, 2017 , a hypothetical further 10% strengthening of the U.S. dollar would not materially affect the Company’s financial statements.
Chart’s primary transaction exchange rate exposures are with the euro, the Japanese yen, the Czech koruna, the Australian dollar, the British pound, and the Chinese yuan. Transaction gains and losses arising from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized in the condensed consolidated statements of operations and comprehensive (loss) income as a component of foreign currency (gain) loss. The Company enters into foreign exchange forward contracts to hedge anticipated and firmly committed foreign currency transactions. Chart does not use derivative financial instruments for speculative or trading purposes. The terms of the contracts are generally one year or less. At March 31, 2017 , a hypothetical 10% weakening of the U.S. dollar would not materially affect the Company’s outstanding foreign exchange forward contracts.
Market Price Sensitive Instruments
In connection with the issuance of the Convertible Notes, the Company entered into privately-negotiated convertible note hedge and capped call transactions with affiliates of certain of the underwriters (the “Option Counterparties”). The convertible note hedge and capped call transactions relate to, collectively, 3.6 million shares, which represents the number of shares of the Company’s common stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those

27
Table of Contents


applicable to the Convertible Notes. These convertible note hedge and capped call transactions are expected to reduce the potential dilution with respect to the Company’s common stock upon conversion of the Convertible Notes and/or reduce the Company’s exposure to potential cash or stock payments that may be required upon conversion of the Convertible Notes, except, in the case of the capped call transactions, to the extent that the market price per share of the Company’s common stock exceeds the cap price of the capped call transactions.
The Company also entered into separate warrant transactions with the Option Counterparties initially relating to the number of shares of the Company’s common stock underlying the convertible note hedge transactions, subject to customary anti-dilution adjustments. The warrant transactions will have a dilutive effect with respect to the Company’s common stock to the extent that the price per share of the Company’s common stock exceeds the strike price of the warrants unless the Company elects, subject to certain conditions, to settle the warrants in cash. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. Further information is located in the Debt and Credit Arrangements note to the Company’s condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
Item 4.
Controls and Procedures
As of March 31, 2017 , an evaluation was performed, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, such officers concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act (1) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (2) is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.
There were no changes in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

28
Table of Contents


PART II. OTHER INFORMATION
Item 1A.
Risk Factors
In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Item 1A. “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 .
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
Issuer Purchases of Equity Securities
Period
Total
Number
of
Shares
Purchased
 
Average Price
Paid Per
Share
 
Total Number of
Shares Purchased
As Part of Publicly
Announced Plans
or Programs
 
Approximate Dollar
Value of Shares
that May Yet Be
Purchased Under
the Plans or
Programs
January 1 – 31, 2017
36,717

 
$
36.37

 
—

 
$
—

February 1 – 28, 2017
11,278

 
39.65

 
—

 
—

March 1 – 31, 2017
305

 
36.59

 
—

 
—

Total
48,300

 
$
37.13

 
—

 
$
—

During the first quarter of 2017 , 48,300 shares of common stock were surrendered to us by participants under our share-based compensation plans to satisfy tax withholding obligations relating to the vesting or payment of equity awards for an aggregate purchase price of approximately $1,793,580 . The total number of shares repurchased represents the net shares issued to satisfy tax withholdings. All such repurchased shares were subsequently retired during the three months ended March 31, 2017 .
Item 4. Mine Safety Disclosures
Not applicable.

29
Table of Contents


Item 6.
Exhibits
The following exhibits are included with this report:
10.1
Employment Agreement, dated February 13, 2017, by and between Chart Industries, Inc. and Jillian C. Evanko. * (x)
10.2
Amendment No. 1, dated December 6, 2016 to the Employment Agreement dated April 15, 2016 by and between Chart Industries, Inc. and Mary C. Cook. * (x)
31.1
Rule 13a-14(a) Certification of Chief Executive Officer (x)
31.2
Rule 13a-14(a) Certification of Chief Financial Officer (x)
32.1
Section 1350 Certification of Chief Executive Officer (xx)
32.2
Section 1350 Certification of Chief Financial Officer (xx)
101.INS
XBRL Instance Document (xxx)
101.SCH
XBRL Taxonomy Extension Schema Document (xxx)
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document (xxx)
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document (xxx)
101.LAB
XBRL Taxonomy Extension Label Linkbase Document (xxx)
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document (xxx)
_______________
(x)
Filed herewith.
(xx)
Furnished herewith.
(xxx)
In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act of 1933 or Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
*
Management contract or compensatory plan or arrangement.



30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Chart Industries, Inc.
(Registrant)
 
Date:
April 27, 2017
By:
/s/ Jillian C. Evanko
 
 
 
Jillian C. Evanko
 
 
 
Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
 
 
(Duly Authorized Officer)


31


Exhibit 10.1
EMPLOYMENT AGREEMENT
_______________

EMPLOYMENT AGREEMENT (the “Agreement”) dated February 13, 2017 by and between Chart Industries, Inc. (the “Company”) and Jillian C. Evanko (the “Executive”).
The Company desires to employ Executive and to enter into an agreement embodying the terms of such employment; and
Executive desires to accept such employment and enter into such an agreement.
In consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties agree as follows:
1. Term of Employment . Subject to the provisions of Section 8 of this Agreement, Executive shall be employed by the Company, on the terms and subject to the conditions set forth in this Agreement, for the period commencing on February 13, 2017, and ending on the second anniversary of said date (the “Employment Term”). Thereafter the Employment Term shall automatically be extended on February 13 of each year for a period of one year from such date. In addition, in the event of a Change in Control, the Employment Term shall automatically be extended for a period of three years beginning on the date of the Change in Control and ending on the third anniversary of the date of such Change in Control (unless further extended under the immediately preceding sentence). The Company or Executive may give notice to the other party that the Employment Term shall no longer be extended (the “Non-Renewal Notice”), in which event the Employment Term shall expire on the latest of: (i) such second anniversary of the original Employment Term commencement date, (ii) such third anniversary of a Change in Control, or (iii) the first anniversary of the delivery of such Non-Renewal Notice. In any case, the Employment Term may be terminated earlier under the terms and conditions set forth herein.
2. Position .

a. Title . During the Employment Term, Executive shall serve as the Company’s Vice President of Finance. In such position, Executive shall have such duties, authority and responsibility as shall be determined from time to time by the Board of Directors of the Company (the “Board”) or the Chief Executive Officer of the Company, which duties, authority and responsibility are consistent with the position of Vice President of Finance of the Company.

b. Best Efforts . During the Employment Term, Executive will devote Executive’s full business time and best efforts to the performance of Executive’s duties hereunder and will not engage in any other business, profession or occupation for compensation or otherwise which would conflict or interfere with the rendition of such services either directly or indirectly, without the prior written consent of the Board; provided that nothing herein shall preclude Executive, subject to the prior approval of the Board, from accepting appointment to or continue to serve on any board of directors or trustees of any business corporation or any charitable organization; provided in each case, and in the aggregate, that such activities do not conflict or interfere with the performance of Executive’s duties hereunder or conflict with Section 10.

c. Place of Employment . The Company shall give Executive at least six months’ advance notice of any proposed relocation of its offices in Canton, Georgia at which Executive’s present principal office is located to a location more than 50 miles from such present location, and, if Executive in Executive’s sole discretion chooses to relocate Executive’s principal residence as a result of such office relocation, the Company shall promptly pay (or reimburse Executive for) all reasonable relocation expenses (consistent with the Company’s past practice for similarly situated senior executive officers) incurred by Executive relating to a change of Executive’s principal residence in connection with any such relocation of the Company’s offices from such present location.

3. Base Salary . During the Employment Term, the Company shall pay Executive a base salary at the annual rate of $415,000, payable in regular installments in accordance with the Company’s usual payment practices. Executive shall be entitled to such increases in Executive’s base salary, if any, as may be determined from time to time in the sole discretion of the Board or any duly authorized committee thereof. Executive’s annual base salary, as in effect from time to time, is hereinafter referred to as the “Base Salary.”





4. Annual Bonus . With respect to each full fiscal year during the Employment Term (commencing with the 2017 fiscal year), Executive shall be eligible to earn an annual bonus award (an “Annual Bonus”) of an amount, expressed as a percentage of Executive’s Base Salary, as determined by the Board, or any duly authorized committee thereof, within the first three months of each fiscal year of the Employment Term (with it being understood that such percentage of Executive’s Base Salary is the “Target”), based upon the achievement of the performance targets established by the Board, or any duly authorized committee thereof, within the first three months of each fiscal year during the Employment Term and communicated to Executive in writing promptly thereafter. For the 2017 fiscal year, Executive’s Target shall be 65% of Executive’s Base Salary, and the performance targets shall be communicated in writing to Executive prior to the commencement of the Employment Term. The Annual Bonus, if any, shall be paid to Executive within two and one-half (2.5) months after the end of the applicable fiscal year. Any Annual Bonus payable hereunder shall be determined in accordance with the terms of the Company’s Cash Incentive Plan, as currently in effect and as it may be amended from time to time, including any successor plan (the “Incentive Compensation Plan”). In the event of a Change In Control as defined in the Incentive Compensation Plan, the annual bonus may be pro-rated in accordance with the terms of the Incentive Compensation Plan.

5. Employee Benefits . During the Employment Term, Executive shall be entitled to participate in the Company’s employee benefit plans (other than annual bonus and incentive plans) providing for health, life and disability insurance, retirement, deferred compensation and fringe benefits, as well as any equity compensation plans, as in effect from time to time (collectively “Employee Benefits”), on the same basis as those benefits are generally made available to other senior executives of the Company. Executive’s right to participate in any Employee Benefits shall be subject to the applicable eligibility criteria for participation and Executive shall not be entitled to any benefits under, or based on, any Employee Benefits for any purposes of this Agreement if Executive does not during the Employment Term satisfy the eligibility criteria for participation in such Employee Benefits. Any equity incentive granted, awarded and held by the Executive shall be governed by the applicable terms of any such grant and award, and shall not be impacted by the terms of this Agreement, except to the extent taken into account in determinations under Section 9.

6. Vacation . During the Employment Term, Executive shall be entitled to four weeks vacation and other paid time off benefits in accordance with applicable Company policies, and to be taken at such times as chosen by Executive.

7. Business Expenses and Perquisites .

a. Expenses . During the Employment Term, reasonable business expenses incurred by Executive in the performance of Executive’s duties hereunder shall be reimbursed by the Company in accordance with Company policies.

b. Perquisites . During the Employment Term, Executive shall be eligible for an automobile allowance of up to $1,000 per month, consistent with the Company’s current practices.

8. Termination . The Employment Term and Executive’s employment hereunder may be terminated by either party at any time and for any reason; provided that Executive will be required to give the Company at least 60 days advance written notice of any resignation of Executive’s employment. The provisions of this Section 8 govern Executive’s rights upon Termination of Employment with the Company and its affiliates. “Termination of Employment” as used in this Agreement means the separation from service, within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended from time to time (“Code”, any reference in this Agreement to a Section of the Code shall include all lawful regulations and pronouncements promulgated thereunder, as well as any successor Sections of the Code having the same or similar purpose), of Executive with the Company and all of its affiliates, for any reason, including without limitation, quit, discharge, or retirement, or a leave of absence (including military leave, sick leave, or other bona fide leave of absence such as temporary employment by the government if the period of such leave exceeds the greater of six months, or the period for which Executive’s right to reemployment is provided either by statute or by contract) or permanent decrease in service to a level that is no more than Twenty Percent (20%) of its prior level. For this purpose, whether a Termination of Employment has occurred is determined based on whether it is reasonably anticipated that no further services will be performed by Executive after a certain date or that the level of bona fide services Executive will perform after such date (whether as an employee or as an independent contractor) would permanently decrease to no more than Twenty Percent (20%) of the average level of bona fide services performed (whether as an employee or an independent contractor) over the immediately preceding 36-month period (or the full period of services if Executive has been providing services less than 36 months). The terms “Terminate” or “Terminated,” when used in reference to Executive’s employment or the Employment Period, shall refer to a Termination of Employment as set forth in this paragraph. “Date of Termination” refers to the effective date of Executive’s Termination of Employment.





a. Termination By the Company For Cause or By Executive Resignation Without Good Reason .

(i) Events . The Employment Term and Executive’s employment hereunder may be terminated by the Company for Cause (as defined below) and shall terminate automatically upon Executive’s resignation without Good Reason (as defined in Section 8(c)); provided that Executive will be required to give the Company at least 60 days advance written notice of a resignation without Good Reason.

(ii) For Cause . For purposes of this Agreement, “Cause” shall mean the Executive’s (A) willful failure to perform duties which, if curable, is not cured promptly, or in any event within ten (10) days, following the first written notice of such failure from the Company, (B) commission of, or plea of guilty or no contest to a (x) felony or (y) crime involving moral turpitude, (C) willful malfeasance or misconduct which is demonstrably injurious to the Company or its subsidiaries or affiliates, (D) material breach of the material terms of this Agreement, including, without limitation, any non-competition, non-solicitation or confidentiality provisions, (E) commission of any act of gross negligence, corporate waste, disloyalty or unfaithfulness to the Company which adversely affects the business of the Company or its subsidiaries or affiliates, or (F) any other act or course of conduct which will demonstrably have a material adverse effect on the Company, a subsidiary or affiliate’s business. For avoidance of doubt, the Company’s failure to achieve its business plan or projections shall not alone be considered “Cause”.

(iii) Compensation . If Executive’s employment is terminated by the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive the amounts in clauses (A) through (D) below referred to herein as “Accrued Rights”:

(A) the Base Salary through the Date of Termination;

(B) any Annual Bonus earned, but unpaid, as of the Date of Termination for the immediately preceding fiscal year, paid in accordance with Section 4 (except to the extent payment is otherwise deferred pursuant to any applicable deferred compensation arrangement with the Company);

(C) reimbursement, within 60 days following submission by Executive to the Company of appropriate supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive’s Termination of Employment; provided claims for such reimbursement (accompanied by appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive’s Termination of Employment; and

(D) such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit plans of the Company, including payment for any accrued but unused vacation within 30 days following the date of Executive’s Date of Termination.

Following such Termination of Employment by the Company for Cause or resignation by Executive without Good Reason, except as set forth in this Section 8(a)(iii), Executive shall have no further rights to any compensation or any other benefits under this Agreement.
b. Disability or Death .

(i) Events . The Employment Term and Executive’s employment hereunder shall terminate upon Executive’s death and may be terminated by the Company if Executive becomes physically or mentally incapacitated and is therefore unable for a period of six (6) consecutive months or for an aggregate of nine (9) months in any twenty-four (24) consecutive month period to perform Executive’s duties (such incapacity is hereinafter referred to as “Disability”). In no event shall an Executive’s employment be continued beyond the 29th month of absence due to Executive’s Disability. Any question as to the existence of the Disability of Executive as to which Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to Executive and the Company. If Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and Executive shall be final and conclusive for all purposes of the Agreement.

(ii) Compensation . Upon Executive’s Termination of Employment hereunder for either Disability or death, Executive or Executive’s estate (as the case may be) shall be entitled to receive:
(A) the Accrued Rights; and





(B) a pro rata portion of the Annual Bonus, if any, that Executive would have been entitled to receive pursuant to Section 4 hereof for such year based upon the Company’s actual results for the year of termination and the percentage of the fiscal year that shall have elapsed through the Executive’s Date of Termination, payable to Executive pursuant to Section 4 had Executive’s employment not terminated.

Following Executive’s Termination of Employment due to death or Disability, except as set forth in this Section 8(b)(ii), Executive shall have no further rights to any compensation or any other benefits under this Agreement.
c. Termination by the Company Without Cause or Resignation by Executive for Good Reason .

(i) Events . The Employment Term and Executive’s employment hereunder may be terminated by the Company without Cause or by Executive’s resignation for Good Reason at any time including during the Protected Period.

(ii) Good Reason . For purposes of this Agreement, “Good Reason” shall mean, without Executive’s consent: (i) a material diminution in Executive’s base salary (excluding any general salary reduction similarly affecting substantially all other senior executives of the Company as a result of a material adverse change in the Company’s prospects or business); (ii) a material diminution in Executive’s authority, duties, or responsibilities (including a change in Executive’s reporting line such that he does not report to the Company’s Chief Executive Officer or the Board); (iii) a material change in the geographic location at which Executive must perform services; or (iv) any other action or inaction that constitutes a material breach by the Company of this Agreement; provided, however, that “Good Reason” shall not be deemed to exist unless: (A) the Executive has provided notice to the Company of the existence of one or more of the conditions listed in (i) through (iv) within 90 days after the initial occurrence of such condition or conditions; and (B) such condition or conditions have not been cured by the Company within 30 days after receipt of such notice. Simply the receipt by the Executive of a Non-Renewal Notice from the Company shall not, in and of itself, be deemed to be an event of “Good Reason” under this Agreement.

(iii) Protected Period . For purposes of this Agreement, “Protected Period” shall mean the period of time commencing on the date of a Change in Control and ending two years after such date.

(iv) Change in Control . For purposes of this Agreement, “Change in Control” shall mean, with respect to the Executive, the happening of any of the following events (but only if with respect to the Executive, such event would constitute a change in the ownership or effective control of the corporation, or in the ownership of a substantial portion of the assets of the corporation, as defined under Section 409A of the Code):

(A) a change in the ownership of the Company (or any affiliate which either employs the Executive or is a direct or indirect parent of such employer) by which any one person, or more than one person acting as a group, acquires ownership of stock of the Company (or such an affiliate) that, together with stock held by such person or group, constitutes more than Fifty Percent (50%) of the total fair market value or total voting power of the stock of the Company (or such an affiliate). However, if any one person, or more than one person acting as a group, is considered to own more than 50% of the total fair market value or total voting power of the stock of the Company (or such an affiliate), the acquisition of additional stock by the same person or persons is not considered to cause a Change in Control. (An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company (or such an affiliate) acquires its stock in exchange for property will be treated as an acquisition of stock for purposes of this definition. This parenthetical phrase applies only when there is a transfer of stock of the Company (or issuance of stock of the Company) (or such an affiliate) and stock in the Company (or such an affiliate) remains outstanding after the transaction.)

(B) a change in effective control of the Company (or any affiliate which either employs the Executive or is a direct or indirect parent of such employer) by which:

(1)     any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the Company (or such an affiliate) possessing Thirty Percent (30%) or more of the total voting power of the stock of the Company (or such an affiliate); or

(2)     a majority of members of the Board of Directors is replaced during any 12-month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board of Directors before the date of the appointment or election.





(C) a change in the ownership of a substantial portion of the assets of the Company (or any affiliate which either employs the Executive or is a direct or indirect parent of such employer) by which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company (or such an affiliate) that have a total gross fair market value equal to or more than Forty Percent (40%) of the total gross fair market value of all of the assets of the Company (or such an affiliate) immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the corporation, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.
For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders only with respect to the ownership in that corporation before the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.
(v) Compensation if Terminated Outside of Protected Period . If, at any time other than during the Protected Period, the Executive’s employment is terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns for Good Reason within 6 months of the condition giving rise to the good reason, Executive shall be entitled to receive:

(A) the Accrued Rights;

(B) subject to Executive’s (x) continued compliance with the provisions of Sections 10 and 11 and (y) execution and delivery of a general release of claims against the Company and its affiliates in a form reasonably acceptable to the Company, payment in one lump sum of:

(1)     150% of the greater of the current Base Salary or Executive’s highest Base Salary paid within the Employment Term; plus

(2)     the greater of (i) 150% of Executive’s Target Annual Bonus for the fiscal year in which Executive’s Termination of Employment occurs or (ii) 150% of Executive’s Target Annual Bonus for the fiscal year immediately preceding the fiscal year in which Executive’s Termination of Employment occurs,

payable to Executive in one lump sum immediately following the expiration of the revocation period provided for in such release, but in no event later than two and a half (2-1/2) months after the end of the year in which the Executive’s Termination of Employment occurred; and
(C) a lump sum payment equal to the premium subsidy the Company would have otherwise paid on Executive’s behalf under the Company’s health insurance plan had he remained employed for the eighteen (18) months period following the Date of Termination.

(vi) Compensation if Terminated during Protected Period . If, during the Protected Period, either the Executive’s employment is Terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns for Good Reason, Executive shall be entitled to receive:

(A) the Accrued Rights;

(B) subject to Executive’s (x) continued compliance with the provisions of Sections 10 and 11 and (y) execution and delivery of a general release of claims against the Company and its affiliates in a form reasonably acceptable to the Company, payment in one lump sum of:

(1)     200% of the greater of the current Base Salary or Executive’s highest Base Salary paid within the Employment Term; plus

(2)     the greater of (i) 200% of Executive’s Target Annual Bonus for the fiscal year in which Executive’s Termination of Employment occurs or (ii) 200% of Executive’s Target Annual Bonus for the fiscal year immediately preceding the fiscal year in which the Change in Control occurs;





payable generally within ten (10) business days after Executive’s Date of Termination, or, if later, upon the expiration of the revocation period provided for in such release, except when such payment is delayed and paid in accordance with Section 9(b) for a determination under Section 9, but in no event later than two and a half (2-1/2) months after the end of the year in which the Executive’s Termination of Employment occurred; and
(C) a lump sum payment equal to the premium subsidy the Company would have otherwise paid on Executive’s behalf under the Company’s health insurance plan had he remained employed for the twenty-four (24) months period following the Date of Termination.

Following Executive’s Termination of Employment by the Company without Cause (other than by reason of Executive’s death or Disability) or by Executive’s resignation for Good Reason, except as set forth in this Section 8(c), Executive shall have no further rights to any compensation or any other benefits under this Agreement.
d. Expiration of Employment Term .

(i) Election Not to Renew the Employment Term . In the event either party provides the other with the Non-Renewal Notice pursuant to Section 1, unless Executive’s employment is earlier terminated pursuant to paragraphs (a), (b) or (c) of this Section 8, the expiration of the Employment Term and the Executive’s Termination of Employment hereunder (whether or not Executive continues as an employee of the Company thereafter) shall be deemed to occur on the close of business on the last day of such Employment Term and Executive shall be entitled to receive the Accrued Rights. The Company’s providing of a Non-Renewal Notice under Section 1 shall not prejudice in any way Executive’s right to assert an event of Good Reason (as such term is defined above), whether related to such Non-Renewal Notice or otherwise, at any time during the Employment Term.

Following such termination of Executive’s employment hereunder, except as set forth in this Section 8(d)(i), Executive shall have no further rights to any compensation or any other benefits under this Agreement.
(ii) Continued Employment Beyond the Expiration of the Employment Term . Unless the parties otherwise agree in writing, continuation of Executive’s employment with the Company beyond the expiration of the Employment Term shall be deemed an employment at-will and shall not be deemed to extend any of the provisions of this Agreement and Executive’s employment may thereafter be terminated at will by either Executive or the Company; provided that the provisions of Sections 10, 11 and 12 of this Agreement shall survive any termination of this Agreement or Executive’s Termination of Employment hereunder.

e. Notice of Termination . Any purported Termination of Employment by the Company or by Executive (other than due to Executive’s death) shall be communicated by written Notice of Termination to the other party hereto in accordance with Section 13(i) hereof. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for Termination of Employment under the provision so indicated.

f. Board/Committee Resignation . Upon termination of Executive’s employment for any reason, Executive agrees to resign, as of the date of such termination and to the extent applicable, from the Board (and any committees thereof) and the Board of Directors (and any committees thereof) of any of the Company’s affiliates.

9. Conditional Reduction in Payments .

a. Notwithstanding anything in this Agreement to the contrary, in the event that it shall be determined (as hereafter provided) that any payment or distribution provided for pursuant to the terms of this Agreement for the benefit of Executive, when aggregated with any other payments or benefits received or receivable by Executive (individually and collectively, a “Payment”), would constitute “parachute payments” within the meaning of Section 280G of the Code, and would be subject to the excise tax imposed by Section 4999 of the Code or to any similar tax imposed by state or local law, or to any interest or penalties with respect to such taxes (such tax or taxes, together with any such interest and penalties, being hereafter collectively referred to as the “Excise Tax”), then Executive’s payments under Section 8 hereof shall be either:

(i) delivered in full, or





(ii) reduced to the minimum extent necessary so that no portion of the Payment, after such reduction, constitutes an Excess Parachute Payment (as defined in Section 280G(b) of the Code) (the amount of such reduction shall be referred to as the “Excess Amount”);

whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.
b. All determinations required to be made under this Section 9, including whether an Excise Tax is payable by Executive and the amount of such Excise Tax and whether a reduction in the Payment is to be made and the amount of such Excess Amount, if any, shall be made by a nationally recognized accounting firm proposed by the Company and reasonably acceptable to Executive (which accounting firm shall be the “Accounting Firm” hereunder). The Company or Executive shall direct the Accounting Firm to submit its determination and detailed supporting calculations to both the Company and Executive within 30 calendar days after the Date of Termination, if applicable, and any other time or times as may be requested by the Company or Executive. The Company shall pay Executive’s payments under Section 8 hereof, as reduced or not reduced pursuant to the final determination of the Accounting Firm and Subsection 9(a) above, no later than the time otherwise required hereunder. If the Accounting Firm determines that no Excise Tax is payable by Executive, it shall, at the same time as it makes such determination, furnish the Company and Executive an opinion that Executive has substantial authority not to report any Excise Tax on Executive’s federal, state or local income or other tax return.

c. As a result of the uncertainty in the application of Section 4999 of the Code and the possibility of similar uncertainty regarding applicable state or local tax law at the time of any determination by the Accounting Firm hereunder, it is possible that, pursuant to a final determination of a court or an Internal Revenue Service proceeding which has been finally and conclusively resolved, an Excess Parachute Payment was received by Executive which would have been intended to be reduced by the Excess Amount pursuant to Subsection 9(a) above. In such case, then such amount received by Executive shall be deemed to be an overpayment, and Executive shall repay the amount equal to the Excess Amount (to the extent received by Executive) to the Company on demand (but no less than ten days after Executive receives written demand).

d. The Company and Executive shall each provide the Accounting Firm access to and copies of any books, records and documents in the possession of the Company or Executive, as the case may be, reasonably requested by the Accounting Firm, and otherwise cooperate with the Accounting Firm in connection with the preparation and issuance of the determinations and calculations contemplated by Subsection 9(b). Any determination by the Accounting Firm as to the amount of any Excess Amount shall be binding upon the Company and Executive.

e. The fees and expenses of the Accounting Firm for its services in connection with the determinations and calculations contemplated by Subsection 9(b) shall be borne by the Company.

10. Non-Competition .

a. Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company and its affiliates and accordingly agrees as follows:

(i) During the Employment Term and the eighteen (18) months following the date of Executive’s Termination of Employment or, if any benefits are paid to Executive pursuant to subparagraph (vi) of Section 8.c of this Agreement, the twenty-four (24) months following the date of Executive’s Termination of Employment (the “Restricted Period”), Executive will not, whether on Executive’s own behalf or on behalf of or in conjunction with any person, firm, partnership, joint venture, association, corporation or other business organization, entity or enterprise whatsoever (“Person”), directly or indirectly solicit or assist in soliciting in competition with the Company, the business of any client or customer or prospective client or customer:

(A) with whom Executive had personal contact or dealings on behalf of the Company during the one year period preceding the earlier of the Executive’s Termination of Employment or such solicitation;

(B) with whom employees reporting to Executive have had personal contact or dealings on behalf of the Company during the one year immediately preceding the Executive’s Termination of Employment; or

(C) for whom Executive had direct or indirect responsibility during the one year immediately preceding Executive’s Termination of Employment.





(ii) During the Restricted Period, Executive will not directly or indirectly:

(A) engage in (1) the business of manufacturing equipment used in (x) the production, storage and end-use of hydrocarbon and industrial gases business or (y) low temperature and cryogenic applications, (2) any other businesses which the Company or its subsidiaries engage in during the term of Executive’s employment with the Company and (3) any businesses which, as of the date of Executive’s Termination of Employment, the Company or its subsidiaries both (x) have specific plans to conduct in the future (and as to which Executive is aware of such planning) and (y) have allocated or invested capital as of the date of such Termination of Employment (a “Competitive Business”);

(B) enter the employ of, or render any services to, any Person (or any division or controlled or controlling affiliate of any Person) who or which engages in a Competitive Business;

(C) acquire a financial interest in, or otherwise become actively involved with, any Competitive Business, directly or indirectly, as an individual, partner, shareholder, officer, director, principal, agent, trustee or consultant; or

(D) interfere with, or attempt to interfere with, business relationships (whether formed before, on or after the date of this Agreement) between the Company or any of its affiliates and customers, clients, suppliers, partners, members or investors of the Company or its affiliates.

(iii) Notwithstanding anything to the contrary in this Agreement, Executive may, directly or indirectly own, solely as an investment, securities of any Person engaged in the business of the Company or its affiliates which are publicly traded on a national or regional stock exchange or quotation system or on the over-the-counter market if Executive (i) is not a controlling person of, or a member of a group which controls, such person and (ii) does not, directly or indirectly, own 5% or more of any class of securities of such Person.

(iv) During the Restricted Period, Executive will not, whether on Executive’s own behalf or on behalf of or in conjunction with any Person, directly or indirectly:

(A) solicit or encourage any employee of the Company or its affiliates to leave the employment of the Company or its affiliates; or

(B) hire any such employee who was employed by the Company or its affiliates as of the date of Executive’s Termination of Employment with the Company or who left the employment of the Company or its affiliates coincident with, or within one year prior to or after, the termination of Executive’s employment with the Company.

(v) During the Restricted Period, Executive will not, directly or indirectly, solicit or encourage to cease to work with the Company or its affiliates any consultant then under contract with the Company or its affiliates.

b. It is expressly understood and agreed that although Executive and the Company consider the restrictions contained in this Section 10 to be reasonable, if a final judicial determination is made by a court of competent jurisdiction that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction against Executive, the provisions of this Agreement shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction contained in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not affect the enforceability of any of the other restrictions contained herein.

11. Confidentiality; Intellectual Property .

a. Confidentiality .

(i) Executive will not at any time (whether during or after Executive’s employment with the Company) (x) retain or use for the benefit, purposes or account of Executive or any other Person other than the Company; or (y) disclose, divulge, reveal, communicate, share, transfer or provide access to any Person outside the Company (other than its professional advisers who are bound by confidentiality obligations or other than in performing his or her duties on behalf of the Company consistent with Company policies), any non-public, proprietary or confidential information--including without limitation trade secrets, know-how, research and development, software, databases, inventions, processes, formulae, technology, designs and other intellectual property, information concerning finances, investments, profits, pricing, costs,




products, services, vendors, customers, clients, partners, investors, personnel, compensation, recruiting, training, advertising, sales, marketing, promotions, government and regulatory activities and approvals -- concerning the past, current or future business, activities and operations of the Company, its subsidiaries or affiliates and/or any third party that has disclosed or provided any of same to the Company on a confidential basis (“Confidential Information”) without the prior written authorization of the Board or a duly authorized committee thereof.

(ii) “Confidential Information” shall not include any information that is (a) generally known to the industry or the public other than as a result of Executive’s breach of this covenant or any breach of other confidentiality obligations by third parties; (b) made legitimately available to Executive by a third party without breach of any confidentiality obligation; or (c) required by law to be disclosed; provided that Executive shall give prompt written notice to the Company of such requirement, disclose no more information than is so required, and cooperate with any attempts by the Company to obtain a protective order or similar treatment.

(iii) Upon termination of Executive’s employment with the Company for any reason, Executive shall (x) cease and not thereafter commence use of any Confidential Information or intellectual property (including without limitation, any patent, invention, copyright, trade secret, trademark, trade name, logo, domain name or other source indicator) owned or used by the Company, its subsidiaries or affiliates; (y) immediately destroy, delete, or return to the Company, at the Company’s option, all originals and copies in any form or medium (including memoranda, books, papers, plans, computer files, letters and other data) in Executive’s possession or control (including any of the foregoing stored or located in Executive’s office, home, laptop or other computer, whether or not Company property) that contain Confidential Information or otherwise relate to the business of the Company, its affiliates and subsidiaries, except that Executive may retain only those portions of any personal notes, notebooks and diaries that do not contain any Confidential Information; and (z) notify and fully cooperate with the Company regarding the delivery or destruction of any other Confidential Information of which Executive is or becomes aware.

b. Intellectual Property .

(i) If Executive has created, invented, designed, developed, contributed to or improved any works of authorship, inventions, intellectual property, materials, documents or other work product (including without limitation, research, reports, software, databases, systems, applications, presentations, textual works, content, or audiovisual materials) (“Works”), either alone or with third parties, at any time during Executive’s employment by the Company and within the scope of such employment and/or with the use of any of the Company’s resources (“Company Works”), Executive shall promptly and fully disclose same, to the best of his or her knowledge, to the Company and hereby irrevocably assigns, transfers and conveys, to the maximum extent permitted by applicable law, all rights and intellectual property rights therein (including rights under patent, industrial property, copyright, trademark, trade secret, unfair competition and related laws) to the Company to the extent ownership of any such rights does not vest originally in the Company.

(ii) Executive shall take all reasonably requested actions and execute all reasonably requested documents (including any licenses or assignments required by a government contract) at the Company’s expense (but without further remuneration) to assist the Company in validating, maintaining, protecting, enforcing, perfecting, recording, patenting or registering any of the Company’s rights in the Company Works. If the Company requests Executive’s assistance pursuant to this paragraph following termination of Executive’s employment, such assistance shall be provided at mutually agreeable times and locations.

(iii) Executive shall not improperly use for the benefit of, bring to any premises of, divulge, disclose, communicate, reveal, transfer or provide access to, or share with the Company any confidential, proprietary or non-public information or intellectual property relating to a former employer or other third party without the prior written permission of such third party. Executive hereby indemnifies, holds harmless and agrees to defend the Company and its officers, directors, partners, employees, agents and representatives from any breach of the foregoing covenant that occurs with Executive’s knowledge or as a result of Executive’s negligent conduct. Executive shall comply with all relevant policies and guidelines of the Company, including regarding the protection of confidential information and intellectual property and potential conflicts of interest. Executive acknowledges that the Company may amend any such policies and guidelines from time to time, and that Executive remains at all times bound by their most current version.

(iv) The provisions of Section 11 shall survive the Executive’s Termination of Employment for any reason.

12. Specific Performance . Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened breach of any of the provisions of Section 10 or Section 11 would be inadequate and the Company would suffer




irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available.

13. Miscellaneous .

a. Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflicts of laws principles thereof.

b. Dispute Resolution . Except as otherwise provided in Section 12 of this Agreement, any controversy, dispute, or claim arising out of, in connection with, or in relation to, the interpretation, performance or breach of this Agreement, including, without limitation, the validity, scope, and enforceability of this section, may at the election of any party, be solely and finally settled by arbitration conducted in Cleveland, Ohio, by and in accordance with the then existing rules for commercial arbitration of the American Arbitration Association, or any successor organization and with the Expedited Procedures thereof (collectively, the "Rules"). Each of the parties hereto agrees that such arbitration shall be conducted by a single arbitrator selected in accordance with the Rules; provided that such arbitrator shall be experienced in deciding cases concerning the matter which is the subject of the dispute. Any of the parties may demand arbitration by written notice to the other and to the Arbitrator set forth in this Section 13(b) ("Demand for Arbitration"). Each of the parties agrees that if possible, the award shall be made in writing no more than 30 days following the end of the proceeding. Any award rendered by the arbitrator(s) shall be final and binding and judgment may be entered on it in any court of competent jurisdiction. Each of the parties hereto agrees to treat as confidential the results of any arbitration (including, without limitation, any findings of fact and/or law made by the arbitrator) and not to disclose such results to any unauthorized person. The parties intend that this agreement to arbitrate be valid, enforceable and irrevocable. In the event of any arbitration with regard to this Agreement, each party shall pay its own legal fees and expenses except to the extent set forth in Section 13(p), provided, however, that the Company agrees to pay the cost of the Arbitrator’s fees.

c. Entire Agreement/Amendments . This Agreement contains the entire understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than those expressly set forth herein. This Agreement may not be altered, modified, or amended except by written instrument signed by the parties hereto.

d. No Waiver . The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

e. Severability . In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby.

f. Assignment . This Agreement, and all of Executive’s rights and duties hereunder, shall not be assignable or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and void ab initio and of no force and effect. This Agreement may be assigned by the Company to a person or entity which is an affiliate or a successor in interest to substantially all of the business operations of the Company. The Company will require any person or entity which is an affiliate or a successor in interest to substantially all of the business operations of the Company to assume all obligations of the Company under this Agreement.

g. Set-Off; No Mitigation . The Company’s obligation to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to set-off, counterclaim or recoupment of amounts owed by Executive to the Company or its affiliates (the “debt”), where such debt is incurred in the ordinary course of the service relationship between Executive and the Company, the entire amount of reduction in any of the Company’s taxable years does not exceed $5,000 and the reduction is made at the same time and in the same amount as the debt otherwise would have been due and collected from Executive. Executive shall not be required to mitigate the amount of any payment provided for pursuant to this Agreement by seeking other employment.

h. Successors; Binding Agreement . This Agreement shall inure to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.





i. Notice . For the purpose of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three days after it has been mailed by United States registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.

If to the Company:
Chart Industries, Inc.
One Infinity Corporate Centre Drive, Suite 300
Garfield Heights, Ohio 44125
Facsimile: (440) 753-1491
Attention:     Chief Financial Officer and General Counsel

If to Executive:
To the most recent address of Executive set forth in the personnel records of the Company.
j. Executive Representation . Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive’s duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound.

k. Prior Agreements . This Agreement supercedes all prior agreements and understandings (including verbal agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive’s employment with the Company and/or its affiliates, except that this Agreement does not supercede any stock option agreement, performance unit agreement, restricted stock unit agreement or indemnification agreement.
 
l. Cooperation . Executive shall provide Executive’s reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive’s employment hereunder. This provision shall survive any termination of this Agreement. If the Company requests Executive’s cooperation pursuant to this paragraph following termination of Executive’s employment, such cooperation shall be provided at mutually agreeable times and locations.

m. Withholding Taxes . The Company may withhold from any amounts payable under this Agreement such Federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation.

n. Counterparts . This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

o. Compliance with Section 409A . Notwithstanding anything herein to the contrary, (i) if at the time of Executive’s Termination of Employment with the Company Executive is a “specified employee” as defined in Section 409A of the Code, and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such Termination of Employment is necessary in order to prevent the imposition of any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive’s Termination of Employment with the Company (or the earliest date as is permitted under Section 409A of the Code), (ii) any reimbursements provided under the Agreement, including, but not limited to, in Sections 2.c., 8.a.(iii)(C) and 13(p), shall be made no later than the end of Executive’s taxable year following Executive’s taxable year in which such expense was incurred; in addition, the amounts eligible for reimbursement, or in-kind benefits to be provided, during any one taxable year under this Agreement may not affect the expenses eligible for reimbursement in any other taxable year under this Agreement, (iii) if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section 409A of the Code, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board or any duly authorized committee thereof, that does not cause such an accelerated or additional tax or result in an additional cost to the Company, and (iv) if (x) any payment under this Agreement is subject to Section 409A and is conditioned upon Executive’s signing a release of claims and (y) the period for Executive to sign the release of claims (and any applicable period to revoke the release) starts in one calendar year and ends in the following calendar year, such payment will be made (or commence) in the second calendar year, subject to




any payment terms provided in this Agreement. The Company shall consult with Executive in good faith regarding the implementation of the provisions of this Section 13(o); provided that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect thereto.

p. Enforcement Costs . The Company is aware that upon the occurrence of a Change in Control the Board of Directors or a shareholder of the Company may then cause or attempt to cause the Company to refuse to comply with its obligations under this Agreement, or may cause or attempt to cause the Company to institute, or may institute, litigation or arbitration seeking to have this Agreement declared unenforceable, or may take, or attempt to take, other action to deny Executive the benefits intended under this Agreement. In these circumstances, the purpose of this Agreement could be frustrated. It is the intent of the Company that Executive not be required to incur the expenses associated with the enforcement of Executive’s rights under this Agreement by litigation, arbitration or other legal action because the cost and expense thereof would substantially detract from the benefits intended to be extended to Executive hereunder, nor be bound to negotiate any settlement of Executive’s rights hereunder under threat of incurring such expenses. Accordingly, if at any time following a Change in Control, it should appear to Executive that the Company has failed to comply with any of its obligations under this Agreement or the Company or any other person takes any action to declare this Agreement void or unenforceable, or institutes any litigation, arbitration or other legal action designed to deny, diminish or recover from Executive the benefits intended to be provided to Executive hereunder, and Executive has complied with all of Executive’s obligations under Sections 10 and 11, then the Company irrevocably authorizes Executive from time to time to retain counsel of Executive’s choice at the expense of the Company as provided in this Section 13(p) to represent Executive in connection with the initiation or defense of any litigation, arbitration or other legal action, whether by or against the Company or any Director, officer, shareholder or other person affiliated with the Company, in any jurisdiction. The Company’s obligations under this Section 13(p) shall not be conditioned on Executive’s success in the prosecution or defense of any such litigation, arbitration or other legal action. Notwithstanding any existing or prior attorney-client relationship between the Company and such counsel, the Company irrevocably consents to Executive entering into an attorney-client relationship with such counsel, and in that connection the Company and Executive agree that a confidential relationship shall exist between Executive and such counsel. The reasonable fees and expenses of counsel selected from time to time by Executive as hereinabove provided shall be paid or reimbursed to Executive by the Company on a regular, periodic basis no later than 30 days after presentation by Executive of a statement or statements prepared by such counsel in accordance with its customary practices, up to a maximum of $250,000 per year for each of the two years following the year in which the Change in Control occurs, provided that Executive presents such statement(s) no later than 30 days prior to the end of Executive’s taxable year following the year in which such expenses were incurred. Notwithstanding the foregoing, this Section 13(p) shall not apply at any time unless a Change in Control has occurred.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

CHART INDUSTRIES, INC.
 
Jillian C. Evanko
("Company")
 
("Executive")
 
 
 
 
 
 
/S/    GERALD F. VINCI        
 
/S/    JILLIAN C. EVANKO    
Gerald F. Vinci
Chief Human Resources Officer
 
 






Exhibit 10.2
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 is effective as of December 19, 2016 and hereby amends the Employment Agreement (the “Agreement”), dated as of April 15, 2016, by and between Mary C. Cook (“Executive”) and Chart Industries, Inc. (the “Company”).

WHEREAS, the Company and Executive desire to amend the Agreement; and

WHEREAS, the parties reserved the right to amend the Agreement pursuant to Section 13.c thereof.

NOW, THEREFORE, pursuant to Section 13.c of the Agreement, and effective as of December 6, 2016, the parties hereby amend the Agreement as follows:

1.
Section 4A of the Agreement is hereby added and shall read as follows:

“4A. Retention Bonus .

(a)
Cash Bonus . If Executive remains in the continuous employ of the Company or one of its affiliates from November 1, 2016 until [December 31, 2017] (the “Retention Period”) and does not relocate to a new location outside of the general Bay Village, OH area, then, subject to Section 4A.e below, Executive shall become entitled to receive a retention bonus in an amount equal to 50% of Executive’s Base Salary as of the end of the Retention Period (or any Base Salary rate that was higher during the Term) (the “Retention Bonus”).
(b)
Treatment of Equity Awards . In addition, if Executive becomes entitled to receive the Retention Bonus pursuant to Section 4A.a above then, subject to Section 4A.e below, (i) all outstanding equity awards held by Executive as of the date of Termination of Employment shall become 100% fully vested and exercisable (for any performance-based awards, such awards will vest at 100% of target) and (ii) the Company will extend the exercise period for each stock option held by Executive as of the date of Termination of Employment until the earlier of (A) five (5) years following the date of Termination of Employment or (B) the stock option’s original expiration date.
(c)
Forfeiture . Except as provided in Section 4A.d below, if Executive’s employment with the Company terminates prior to the end of the Retention Period, Executive will forfeit any right to the Retention Bonus and the Company shall have no obligation to make any payment with respect to such Retention Bonus. In addition, if Executive relocates to a new location outside of the general Bay Village, OH area prior to the end of the Retention Period, she will forfeit her right to the Retention Bonus.
(d)
Termination without Cause or for Good Reason . Notwithstanding any provision herein to the contrary, if, prior to the end of the Retention Period, the Company terminates Executive’s employment without Cause or Executive terminates her employment for Good Reason, then, subject to Section 4A.e below, Executive shall become entitled to receive the Retention Bonus, the vesting of outstanding equity awards and the extended stock option exercise period (or the cash payment in lieu thereof) as provided in Section 4A.b above.
(e)
Release Requirement . Notwithstanding any provision herein to the contrary, Executive’s right to receive the Retention Bonus and receive the treatment for her outstanding equity awards provided for in Section 4A.b above shall be subject to and conditioned upon Executive’s execution and delivery of a general release of claims against the Company and its affiliates in a form reasonably acceptable to the Company (the “Release”) and such Release must become effective and irrevocable no later than sixty (60) days following the end of the Retention Period (or the date of Executive’s Termination of Employment, if earlier).
(f)
Payment . The Retention Bonus, if earned, will be paid to Executive, and the vesting of the equity awards shall occur, as soon as administratively practicable following the date on




which Executive’s Release becomes effective and irrevocable, but no later than two and one-half (2 ½) months following the end of the calendar year in which the Retention Period ends.
2.
This Amendment shall only modify the Agreement as set forth herein. All other terms and conditions of the Agreement shall remain in full force and effect.

3.
Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms set forth in the Agreement.


IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment.

CHART INDUSTRIES, INC.
 
Mary C. Cook
("Company")
 
("Executive")
 
 
 
Date: March 6, 2017
 
 
/S/ JILLIAN C. EVANKO       
 
/S/    MARY C. COOK       
Chief Financial Officer
 
Chief Accounting Officer and Controller, Finance






Exhibit 31.1
CERTIFICATION
I, Samuel F. Thomas, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Chart Industries, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 27, 2017
 
    /s/ Samuel F. Thomas
 
Samuel F. Thomas
 
Chairman of the Board and Chief Executive Officer





Exhibit 31.2
CERTIFICATION
I, Jillian C. Evanko, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Chart Industries, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 27, 2017
 
    /s/ Jillian C. Evanko
 
Jillian C. Evanko
 
Chief Financial Officer





Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Chart Industries, Inc., a Delaware corporation (the “ Company ”), does hereby certify, to such officer's knowledge, that:

(a)
The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017 (the “ Form 10-Q ”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.

Dated: April 27, 2017
 
  /s/ Samuel F. Thomas
 
Samuel F. Thomas
 
Chairman of the Board and Chief Executive Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.





Exhibit 32.2
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Chart Industries, Inc., a Delaware corporation (the “ Company ”), does hereby certify, to such officer's knowledge, that:
 
(a)
The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017 (the “ Form 10-Q ”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.

Dated: April 27, 2017
 
  /s/ Jillian C. Evanko
 
Jillian C. Evanko
 
Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.